 
 
Official Title: Zoster Eye Disease Study (ZEDS):  
A multi -center, randomized, double- masked, placebo- controlled clinical 
trial of suppressive valacyclovir for one year in immunocompetent study 
participants with an epi[INVESTIGATOR_242062], s tromal 
keratitis, endothelial keratitis, and/or iritis due to Herpes Zoster 
Ophthalmicus (HZO) in the year prior to enrollment.  
NCT Number : [STUDY_ID_REMOVED]  
Study Number:   
 s16-[ZIP_CODE] 
Document Type:   Study Protocol and Statistical Analysis Plan  
Date of the 
Document:  • March 25, 2020  
 
 
 
   Zoster Eye Disease Study (ZEDS):  
A multi -center, randomized, double -masked, placebo -
controlled clinical trial of suppressive valacyclovir for one 
year in immunocompetent study participants with an epi[INVESTIGATOR_242063], stromal keratitis, 
endothelial keratitis, and/or  iritis due to Herpes Zoster 
Ophthalmicus (HZO) in the year prior to enrollment.  
 
Protocol Identifying Number: 16-[ZIP_CODE]  
Principal Investigator:  [INVESTIGATOR_242064], MD  
Funded by : [CONTACT_242124]:  3.[ADDRESS_293844] OF ABBREVIATIONS  ................................ ................................ ................................ ................................ ...... 5 
STATEMENT OF COMPLIANCE  ................................ ................................ ................................ ............................  7 
PROTOCOL S UMMARY  ................................ ................................ ................................ ................................ ...........  8 
SCHEMATIC OF STUDY DESIGN  ................................ ................................ ................................ .......................  10 
1 KEY ROLES  ................................ ................................ ................................ ................................ .................  11 
2  INTRODUCTION: BACKG ROUND INFORMATION AND SCIENTIFIC RATIONALE ......................  12 
2.1 Background Information  ................................ ................................ ................................ ...................  12 
2.2 Rationale  ................................ ................................ ................................ ................................ ............  16 
2.3 Potential Risks and Benefits  ................................ ................................ ................................ ............  17 
2.3.1  Known Potential Risks  ................................ ................................ ................................ .. 17 
2.3.2  Known Potential Benefits  ................................ ................................ .............................  20 
3 OBJECTIVES AND PURPOSE  ................................ ................................ ................................ .................  20 
4 STUDY DESIGN AND ENDPOINTS  ................................ ................................ ................................ ........  21 
4.1 Description of the Study Design  ................................ ................................ ................................ ..... 21 
4.2.1  Primary Endpoint  ................................ ................................ ................................ ...........  22 
4.2.2  Seco ndary Endpoints  ................................ ................................ ................................ .... 22 
4.2.3  Exploratory Endpoints  ................................ ................................ ................................ ... 23 
5 STUDY ENROLLMENT AND WITHDRAWAL  ................................ ................................ ........................  23 
5.1 Participant Inclusion Criteria  ................................ ................................ ................................ ............  23 
5.2 Participant Exclusion Criteria  ................................ ................................ ................................ ..........  24 
5.3 Strategies for Recruitment and Retention  ................................ ................................ .....................  25 
5.4 Participant Withdrawal or termination  ................................ ................................ ............................  25 
5.4.1  Handling of Participant Withdrawals or termination  ................................ .................  25 
5.5 Premature Termination or Suspension of Study  ................................ ................................ ..........  26 
6 STUDY AGENT  ................................ ................................ ................................ ................................ ...........  26 
6.1 Study Agent(s) a nd Control Description  ................................ ................................ ........................  [ADDRESS_293845] Storage and Stability  ................................ ................................ ......................  27 
6.1.4  Preparation  ................................ ................................ ................................ .....................  27 
6.1.5  Dosing and Administration  ................................ ................................ ...........................  27 
6.1.6  Route of Administration  ................................ ................................ ................................  27 
6.1.7  Starting Dose and Dose Escalation Schedule  ................................ ..........................  27 
6.1.8  Dose Adjustments/Modifications/Delays  ................................ ................................ .... 27 
6.1.9  Duration of Therapy  ................................ ................................ ................................ ...... 29 
6.1.10  Tracking of Dose  ................................ ................................ ................................ ...........  29 
6.1.11  Device Specific Considerations  ................................ ................................ ...................  30 
6.2 Study agent Accountability Procedures  ................................ ................................ .........................  30 
7 STUDY PROCEDURES AND SCHEDULE  ................................ ................................ .............................  30 
7.1 Study Procedures/Evaluations  ................................ ................................ ................................ ........  [ADDRESS_293846] of care study procedures ................................ ................................ .............  30 
7.2 Laboratory Procedures/Evaluations  ................................ ................................ ...............................  31 
7.2.1  Clinical Laboratory Evaluations  ................................ ................................ ...................  31 
7.2.2  Other Assays or Procedures ................................ ................................ ........................  31 
 
iii 
 7.2.3  Specimen Preparation, Handling, and Storage  ................................ ........................  31 
7.2.4  Specimen Shipment  ................................ ................................ ................................ ...... 31 
7.3 Study Schedule  ................................ ................................ ................................ ................................ . 31 
7.3.1  Screening/consent ................................ ................................ ................................ .........  31 
7.3.2  Enro llment/RANDOMIZATION  ................................ ................................ ....................  32 
7.3.3  Follow -up STUDY VISITS  ................................ ................................ ............................  33 
7.3.4  Final Study Visit  ................................ ................................ ................................ .............  34 
7.3.5  Early Termination Visit  ................................ ................................ ................................ .. 34 
7.3.6 Non-STUDY VISIT (Unscheduled/SCHEDULED Visit)  ................................ ...........  34 
7.3.7  Schedule of Events Table  ................................ ................................ ............................  34 
7.4 Justification for Sensitive Procedures  ................................ ................................ ............................  36 
7.5 Concomitant Medications, Treatments, and Procedures  ................................ ............................  36 
7.5.1  Precautionary Medications, Treatments, and Procedures  ................................ ...... 36 
7.6 Prohibited Medications, Treatments, and Procedures  ................................ ................................  36 
7.7 Prophylactic Medications, Treatments, and Procedures  ................................ .............................  36 
7.8 Rescue Medications, Treatments, and Procedures  ................................ ................................ ..... 36 
7.9 Particip ant Access to Study Agent At Study Closure  ................................ ................................ .. 36 
8 ASSESSMENT OF SAFETY  ................................ ................................ ................................ .....................  37 
8.1 Specification of Safety Parameters  ................................ ................................ ................................  37 
8.1.1  Collection of Selected Adverse Events (AE)  ................................ .............................  37 
8.1.2  Definition of Serious Adverse Events (SAE)  ................................ .............................  37 
8.1.3  Definition of Unanticipated (UNEXPECTED) Problems  ................................ ..........  37 
8.2 Classification of an Adverse Event  ................................ ................................ ................................ . 38 
8.2.1  Severity of Event  ................................ ................................ ................................ ...........  38 
8.2.2  Relationship to Study Agent  ................................ ................................ ........................  38 
8.2.3  Expectedness  ................................ ................................ ................................ ................  39 
8.3 Time Perio d and Frequency for Event Assessment and Follow -Up ................................ ..........  39 
8.4 Reporting Procedures  ................................ ................................ ................................ ......................  39 
8.4.1  Adverse Event Reporting  ................................ ................................ .............................  39 
8.4.2 Serious Adverse Event Reporting  ................................ ................................ ...............  39 
8.4.3  unexpected/Unanticipated Problem Reporting  ................................ .........................  [ADDRESS_293847]  ................................ ................................ ............................  40 
8.4.5  Reporting of Pregnancy  ................................ ................................ ................................  40 
8.5 Study Halting Rules  ................................ ................................ ................................ ..........................  40 
8.6 Safety Oversight  ................................ ................................ ................................ ................................  40 
9 CLINICAL MONITORING ................................ ................................ ................................ ...........................  41 
10 STATISTICAL CONSIDERATIONS  ................................ ................................ ................................ ..........  42 
10.1  Statistical Analysis Plan  ................................ ................................ ................................ ...................  42 
10.2  Statistical Hypotheses  ................................ ................................ ................................ ......................  42 
10.3  Analysis datasets  ................................ ................................ ................................ ..............................  44 
10.4  Descr iption of Statistical Methods  ................................ ................................ ................................ .. 44 
10.4.1  General Approach  ................................ ................................ ................................ .........  44 
10.4.2  Analysis of the primary efficacy endpoint(s)  ................................ ..............................  44 
10.4.3  Analysis of the Secondary Endpoint(s)  ................................ ................................ ...... 45 
10.4.4  Exploratory Analyses  ................................ ................................ ................................ .... 45 
10.4.5  Safety Analyses  ................................ ................................ ................................ .............  45 
 
iv 
 10.4.6  Adherence and Retention Analyses  ................................ ................................ ...........  45 
10.4.7  Baseline Descriptive Statistics  ................................ ................................ ....................  46 
10.4.8  Planned Interim Analyses  ................................ ................................ ............................  46 
10.4.9  Additional Sub -group Analyses  ................................ ................................ ...................  46 
10.4.10  Multiple Comparison/Multiplicity  ................................ ................................ ..................  46 
10.4.11  Exploratory Analyses  ................................ ................................ ................................ .... 47 
10.5  Sample Size  ................................ ................................ ................................ ................................ .......  47 
10.6  Measures to Minimize Bias  ................................ ................................ ................................ ..............  47 
10.6.1  Enrollment/ Randomization/ Masking Procedures  ................................ ...................  47 
10.6.2   Evaluation of Success of Blinding  ................................ ................................ ..............  48 
10.6.3  Breaking the Study Blind/Participant Code  ................................ ...............................  48 
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  ................................ .. 48 
12 QUALITY ASSURANCE AND QUALITY CONTROL  ................................ ................................ .............  48 
13 ETHICS/PROTECTION OF HUMAN SUBJEC TS ................................ ................................ ..................  [ADDRESS_293848] POLICY  ................................ ................................ ................................ .........  52 
17  LITERATURE REFERENCES  ................................ ................................ ................................ ...................  52 
APPENDIX  ................................ ................................ ................................ ................................ ................................  58 
 
Zoster Eye Disease Study (ZEDS)  Version 3.[ADDRESS_293849]  
HIV Human Immunodeficiency Virus  
HUS  Hemolytic Uremic Syndrome  
HZ  Herpes Zoster  
HZO  Herpes Zoster Ophthalmicus  
IC50  Inhibitory Concentration to Reduce by 50%  
ICF Informed Consent Form  
Zoster Eye Disease Study (ZEDS)  Version 3.[ADDRESS_293850] Randomized Controlled (Clinical) Trial  
RZV Recombinant Zoster Vaccine  
SAE Serious Adverse Event  
SAP Statistical Analysis Plan  
TMF Trial Master File  
TTP Thrombotic Thrombocytopenic P urpura  
V1 and V2  Cranial Nerve five ( Trigeminal Nerve), first and second division  
VZV  Varicella Zoster Virus  
ZBPI  [INVESTIGATOR_242065] (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  7 STATEMENT OF COMPLIA NCE  
 
The trial will be conducted in accordance with the ICH E6  (R2) Guideline for Good Clinical Practice , the U.S. 
Code of Federal Regulations on the Protection of Human Subjects (45 CFR Part 46), the Code of Federal 
Regulations applicable to clinical studies  (21 CFR 312 – Investigational New Drug Application,  21 CFR 50 – 
Protection of Human Subjects and 21 CFR 54 – Financial Disclosure by [CONTACT_242125],  21 CFR 56 – 
Institutional Review Boards ), and the National Eye Instit ute Terms of Award. The Principal Investigator [INVESTIGATOR_242066] (PCC) will assure that no deviation from, or changes to the protocol will take place 
without prior agreement from the sponsor and documented approval from the Institutional R eview Board (IRB), 
except where necessary to eliminate an immediate hazard(s) to the study participants. All personnel involved 
in the conduct of this study have completed Human Subjects Protection Training.  
 
I agree to ensure that all staff members involv ed in the conduct of this study are informed about their 
obligations in meeting the above commitments.  
 
 
 
 
PCC Principal Investigator  (PI):        
 
 
 
 
PCC PI [INVESTIGATOR_7496] :           Date:       
Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  8 PROTOCOL SUMMARY  
 
Title:  Zoster Eye Disease Study (ZEDS): A multi -center,  randomized, 
double -masked, placebo -controlled clinical trial of valacyclovir for 
one year in immunocompetent study participants with an epi[INVESTIGATOR_242067], stromal keratitis, endothelial keratitis, 
and/or iritis due to  Herpes Zoster Ophthalmicus (HZO) in the year 
prior to enrollment.  
 
Précis:  The study is a double -masked, multi -center, randomized clinical trial 
(RCT) that will enroll immunocompetent study participants age [ADDRESS_293851], with an epi[INVESTIGATOR_242062], stromal 
keratitis, endothelial keratitis, and/or iritis due to HZO in the year 
prior to enrollment . Eligible study participants will be randomized in a 
1:1 ratio to long -term sup pressive treatment with oral valacyclovir 
1000 mg daily or placebo for one year, and followed every 3 months 
for a total of 18 months, to determine outcomes of new or worsening 
dendriform epi[INVESTIGATOR_242068], stromal keratitis, endothelial keratitis, 
and/or iritis and severity and duration of postherpetic neuralgia 
during 12 months of treatment and for 6 months following treatment 
discontinuation. Participants will be randomized within center in  four 
strata, defined by [CONTACT_242126] (less than 60 years or 60 
years and greater) and by [CONTACT_242127] (recent onset 
defined as HZO diagnosed within 6 months of 
enrollment/randomization, or chronic defined as HZO diagnosed 6 
months or more  prior to enrollment/randomization).  
 
Objectives:  
 To evaluate whether or not prolonged suppressive oral antiviral 
treatment with valacyclovir reduces complications of HZO including 
new or worsening dendriform epi[INVESTIGATOR_242068], stromal keratitis, 
endothelial keratitis, and/or iritis and/or postherpetic neuralgia 
compared to placebo.  
  
Endpoint : The primary endpoint is the time to first occurrence of new or 
worsening epi[INVESTIGATOR_242062], stromal keratitis, 
endothelial keratitis, and/or iritis due to HZO, during the twelve 
months of treatment, requiring pre -specif ied treatment  changes.  The 
primary endpoint is compared for participants randomized to study 
medication or placebo  
Population:  Immunocompetent participants age [ADDRESS_293852] 
diagnosis of HZO  that included:  
 Cranial nerve V1 or V2 involvement with history of typi[INVESTIGATOR_242069] 
 Medically documented epi[INVESTIGATOR_242070], stromal keratitis, endothelial keratitis, and/or iritis 
due to HZO in the year prior to enrollment.  
 
Phase:  NIH defined Phase 3 (FDA defined Phase 4)  
 
Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  9 Number of 
Participating Clinical 
Center s (PCC)  
 Approximately  70-80  PCCs  
 
 
Description of Study 
Agent:  Valacyclovir: two 500 mg pi[INVESTIGATOR_242071]: encapsulated matching placebo  
 
Study Duration:  Estimated 8 years: 12 months treatment and additional follow -up 
period up to  6 months.  
 
Participa nt Duration:  Up to 18 months (12 months receiving study medication)  
 
  
Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  10 SCHEMATIC OF STUDY D ESIGN  
 
  

Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  11 1 KEY ROLES  
 
Principal Investigator /Study Chair  
 Elisabeth Cohen, MD  
ZEDS Coordinating Center  
NYU School of Medicine  
One Park Ave, 6th floor, 6 -663 
[LOCATION_001], NY [ZIP_CODE]  
[PHONE_5053]  
[EMAIL_4662]  
 
Study Co -Chair  Bennie Jeng, MD  
University of Maryland School of Medicine  
[ADDRESS_293853]  
Baltimore, MD [ZIP_CODE]  
[PHONE_5054]  
[EMAIL_4663]   
 
NEI Project Officer  Sangeeta Bhargava, PhD  
Division of Extramural  Science Programs  
CCR/NEI/NIH  
Suite 1300, [ADDRESS_293854], MSC 9300  
Bethesda, MD  [ZIP_CODE]  
[PHONE_5055]  
[EMAIL_4664]   
 
  
Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  12 2  INTRODUCTION: BAC KGROUND INFORMATION AND SCIENTIFIC RATIO NALE  
 
2.1 BACKGROUND INFOR MATION  
 
Herpes Zoster Ophthalmicus (HZO) is associated with unilateral acute and chronic eye disease and pain, with 
potential complications that can significantly impair functioning and reduce quality of life (QOL) among millions 
of Americans, especially older adults. Although there is considerable consensus on treatment of acute HZO in 
immunocompetent adults, there is no standard approach to treatment of HZO sequelae such as ocular disease 
and postherpetic neuralgia (PHN), a severely debilitating chronic pain syndrome . Several factors call for 
evaluating long -term suppressive antivirals to prevent HZO complications in a randomized controlled trial : 
recent discoveries about the infectious pathogenesis of complications of herpes zoster (HZ) and HZO; the 
significant benefit of suppressive antivirals in reducing recu rrent herpes simplex virus (HSV) stromal keratitis; 
and evidence of comparable, marked benefit of suppressive antiviral treatment of chronic HZO and HSV in a 
retrospective study (1-4). HZO and HSV eye disease have some clinical similarities in that primary  infection 
(with these different herpes viruses) is followed by [CONTACT_242128], and recurrent infection is frequently associated with 
chronic and/or recurrent eye disease, both of which can lead to loss of vision.  HZ results from acute 
reactivation of latent var icella zoster virus (VZV). It was confirmed only recently, however, that complications of 
HZ may be associated with chronic or recurrent active infection rather than manifestations of inflammatory, 
immune, neuropathic and vascular sequelae of infection.  For example, a 1995 study showed that late 
dendriform epi[INVESTIGATOR_242072] (PCR) positive for VZV, and this was 
confirmed by a larger series in 2010 (2, 3) .  Dendriform  epi[INVESTIGATOR_242073]: further evidence it is caused by [CONTACT_242129] (3, 5) .  There is also evidence 
associating chronic, active VZV infection with PHN , vasculopathy after HZ resulting in potentially fatal strokes , 
and giant cell (temporal) arteritis  (6-9).  The concept that persistent active infection results in chronic HZO has 
generated interest and debate among experts.  A 2012 editorial in Archives of Ophthalmology suggested that, 
“…although stromal keratitis or  uveitis may not represent active viral infection, clinicians may question whether 
subclinical or intermittent viral shedding may help to perpetuate destructive, inflammatory, anterior segment 
disease in HZO” (10).  Corneal changes that result in visual lo ss from VZV keratitis are estimated by [CONTACT_242130] 20 -40% of cases.  In a recent report, the mean number of recurrences of HZO was 
decreased with antiviral treatment from 3.4 epi[INVESTIGATOR_242074] 2.1 epi[INVESTIGATOR_11114] (p<0.05) suggestin g 
that prolonged long -term antivirals at the higher dose to be used in the Zoster Eye Disease Study ( ZEDS) trial 
may reduce morbidity, including visual loss , associated with chronic HZO, and could significantly reduce the 
disease burden for patients and th e costs to society (1).  
 
ZEDS seeks to answer this question for HZO caused by [CONTACT_242131] 
(HEDS) Acyclovir Prevention Trial (APT) did for HSV ocular disease, with a double -masked, placebo -
controlled, multi -center randomized c ontrolled trial (RCT) in immunocompetent study participants age [ADDRESS_293855] diagnosis of HZO and an epi[INVESTIGATOR_242062], stromal keratitis, 
endothelial keratitis, and/or iritis diagnosed within the past year (4).  In HED S, prolonged suppressive antiviral 
treatment was most beneficial in preventing recurrence of stromal keratitis, suggesting that active viral infection 
is an important factor contributing to stromal keratitis, although the mechanism is not understood (4). The 
ZEDS design is analogous to the HEDS design.  Study participants with HZO will be randomized in a double -
masked, placebo -controlled RCT to 1 year of suppressive antiviral treatment with oral valacyclovir or placebo, 
with follow -up every 3 months for a total of 18 months, to compare the rates of new or  worsening dendriform 
Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  13 epi[INVESTIGATOR_242068], stromal keratitis, endothelial keratitis, or iritis and severity and duration of PHN by 12 
months of treatment and 6 months after treatment.  
 
Evidence of Chronic Active VZV Infection after HZ and HZO  
The rational e for the study includes the increasing body of evidence that chronic active VZV infection occurs 
after HZ and contributes to complications, including PHN, stroke, and temporal arteritis, in addition to 
dendriform epi[INVESTIGATOR_242075] (11-14).  VZV DNA has been found to persist in the saliva of 67% 
(21/32) of persons age 60 and older with a history of HZ up to 12 years after disease onset (15).  In HZO, 
evidence from PCR testing shows that active VZV infection contributes to late dendriform epi[INVESTIGATOR_242068], a 
characteristic manifestation of HZO with median occurrence 5 months after HZO onset, and uveitis (2, 3, 14) . 
The finding of VZV DNA in blood mononuclear cells of HZ patients with PHN, in the arteries of patients with 
zoster -related stro kes, and, most recently, in temporal arteries of patients with possible and proven giant cell 
arteritis, is helpi[INVESTIGATOR_242076], the 
importance of accurate diagnosis, and the potential for improved antiviral treatment of these conditions. Given 
evidence that active VZV infection contributes to PHN, and the lack of effective and well tolerated treatment for 
PHN, it is important to study the efficacy of suppressive antiviral treatment for this extremely painful and 
debilitating condition that negatively impacts QOL , especially in the elderly , by [CONTACT_242132].  The results with regard to PHN may be generalizable to HZ in other 
anatomic locations; PHN lasts more than a year in nearly half of patients older than age 70, reduces QOL  in 
direct proportion to the severity and duration of pain, and more than quadruples the one year costs of the 
disease.  In 2014, HZ was reported as a risk factor for myocardial infarction in addition to cerebrovascular 
disease (16-18).  An editorial in Clinical Infectious Diseases concludes, “The growing awareness of the role of 
VZV in va scular disease promises to lead to clinical trials to assess the benefit of antiviral therapy.” (19)  
 
HEDS: Oral Antivirals to Reduce Recurrent Ocular HSV Disease  
The HEDS APT examined long -term use of oral acyclovir to prevent recurrent HSV disease, and found a 45% 
reduction (95% CI 0.41 -0.75, p<0.001) in recurrent ocular disease over 1 year (4).  On the basis of this 
landmark study, recommended care for HSV eye disease changed to include prolonged suppressive antiviral 
treatment.   In HEDS, although high -dose oral antiviral therapy for [ADDRESS_293856] beneficial in 
preventing recurrence of this form of disease in study participants who had a history of stromal keratitis, 
reducing it from 28% to 14% (95% CI 0.29 -0.80, p=0.005)  (4, 20). The efficacy of suppressive antiviral 
treatment in preventing s tromal keratitis and lack of efficacy of high -dose antiviral treatment for stromal keratitis 
are consistent with greater efficacy of prolonged suppressive antiviral treatment in general.  The clinical benefit 
was greater for stromal keratitis than dendriti c keratitis because stromal keratitis results in more scarring and 
permanent damage than superficial epi[INVESTIGATOR_018] (dendritic) keratitis (4). There is no direct evidence that viral 
reactivation causes HSV stromal keratitis, yet HEDS showed that suppression of  HSV reduces the rate of 
recurrence of HSV stromal keratitis. There is an absence of direct evidence that viral replication contributes to 
either HZO or HSV stromal keratitis.  
Prolonged suppressive antiviral treatment has improved outcomes of ocular HSV. T he HEDS trial results were 
observed in a real -world setting. A retrospective community -based cohort study investigating the impact of 
prophylactic antiviral treatment for HSV keratitis, published in 2010, concluded that patients were significantly 
less lik ely to have recurrent HSV epi[INVESTIGATOR_242077] 
(21).  
 
Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  14 We hypothesize that prolonged suppressive valacyclovir treatment will reduce the occurrence of stromal 
keratitis and dendriform epi[INVESTIGATOR_242078].   HSV stromal keratitis is primarily immune -
mediated; while the trigger or mechanism of recurrent inflammation is uncertain, there is strong clinical 
evidence that suppressive antiviral treatment decreases its frequency (22).  HSV and VZV stromal keratitis are 
analogous diseases, and our aim is to determine whether VZV stromal keratitis can be reduced by [CONTACT_242133] a similar fashion to HSV stromal keratitis. If results of the trial are similar with regard to  
antiviral suppression reducing infectious and inflammatory chronic ocular disease in HZO, the benefits to 
patients will be significant as this therapy is adopted as standard of care.  
 
Preliminary Studies  
In preparation for this trial, study leaders conducted and published a retrospective study of over 100 HZO 
patients treated at a tertiary referral center and found that late dendriform epi[INVESTIGATOR_242079]  60 at time of HZO onset compared with those age 60 or older at onset 
(36% vs. 17%, p=0.03)  (23).  Younger patients averaged 3.2 epi[INVESTIGATOR_242080], and older 
patients 1.5 during follow -up (p=0.01).  In both groups, over 80% of patients rem ained on topi[INVESTIGATOR_242081]. Complications including PHN, neurotrophic keratitis and secondary 
infected corneal ulcers were all significantly more common in older -onset patients (38% for those age 60 or 
older at onset vs.  8% for those under age 60 at onset, p=0.001, 31% v. 9% p=0.005, and 17% v. 3%, p=0.04, 
respectively) (23).  
 
Current Practice Patterns and Opi[INVESTIGATOR_6153]  
A survey of 100 corneal specialists was also conducted in preparation for this study; over 85% of specialists 
reported treating cases of chronic or recurrent HZO in the preceding year.   They reported prescribing oral 
antivirals most often for 7 -14 days (37%), while some used them for a year or longer (15%), and others as long 
as patients were on topi[INVESTIGATOR_235980] (15%)  (24).  
 
Suppressive Antivirals Preferred by [CONTACT_242134] (25).  This survey was sent to ophthalmologists, includi ng leaders of cornea fellowship training 
programs and/or cornea subspecialty societies, and to those with special interest in cornea, as indicated by 
[CONTACT_242135] -net, the official forum and listserv of the Cornea Society.   The 171 respondents inc luded 
69% (46/67) of the cornea leaders surveyed.  Valacyclovir 500 mg bid was the preferred antiviral regimen 
(36%), followed by [CONTACT_242136] 800 mg bid (33%), valacyclovir 1000 mg daily (28%), and finally, famciclovir 250 
mg bid (4%).  Further, over 60% of the survey respondents were definitely interested in participating in the 
study.  
 
Pi[INVESTIGATOR_242082].   An observational study from an Ocular Immunology and Uveitis Service at an Italian referral 
center treating patients with chronic HZO, published in 2014, looked at patients who were routinely prescribed 
suppressive antiviral treatment.  The study found tha t in patients who were referred an average of 3 years after 
disease onset, prolonged treatment with antiviral valacyclovir 500 mg daily or acyclovir 400 mg bid reduced the 
overall number of recurrences to 2.1 per year, compared to 3.4 epi[INVESTIGATOR_242083], a 35% 
reduction (p<.05) (1).  In this study, the same suppressive antiviral treatment of HSV keratitis reduced 
recurrences to 2.3 from 3.8, a 39% reduction (p<0.05).  The percent reduction of recurrent HSV (39%) was 
comparable to the perce nt reduction of HSV (45%) in HEDS, and comparable to the reduction of recurrent 
Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  15 inflammation in HZO (35%) in this observational study.  This pi[INVESTIGATOR_242084] 
(30%) postulated for the ZEDS RCT.  This observational study also p rovides data on the relative prevalence of 
types of recurrences: inflammation recurred in 51% of HZO patients followed for an average of 2 years (range 
1-6 years), including stromal keratitis (20%) followed by [CONTACT_242137] (13.3%), keratouveitis (8.9%)  and 
epi[INVESTIGATOR_242068] (6.7%). Inflammation recurred in 65% of HSV patients, including stromal keratitis (24.9%), 
keratouveitis (18.6%), anterior uveitis (14.8%), and epi[INVESTIGATOR_242068] (6.3%).   In both HZO and HSV, stromal 
keratitis and/or uveitis we re the most common forms of recurrent disease: epi[INVESTIGATOR_242085].  Of note, the suppressive antiviral regimen used was weaker (valacyclovir 500 mg daily or acyclovir 
400 mg bid) than treatment planned for the current study (valacyclovir  1000 mg daily), suggesting that using a 
stronger regimen the effect may be even greater.  
 
Remaining Gaps in Knowledge  
The morbidity associated with chronic HZO is substantial and greater than HZ in other anatomic locations due 
to eye disease, longer dura tion of PHN, and greater risk of stroke. Thus, determining whether long -term 
antiviral therapy reduces the disease burden for patients and costs to society will fill a critical, substantial gap. 
Another significant gap in current clinical knowledge relates  to effectiveness of early vs. delayed suppressive 
treatment.   ZEDS will study patients with HZO of recent onset to determine if early suppressive antiviral 
treatment reduces chronic disease, and also patients with chronic disease to determine if delayed t reatment is 
effective.  Furthermore, ZEDS will evaluate the effects of age at disease onset, since this variable affects 
disease manifestations and may affect response to treatment.  Patients with disease onset before age [ADDRESS_293857] 
PHN and problems related to neurotrophic keratopathy (23).  It is unknown if antiviral suppression benefits 
both age groups and whether the risk -benefit ratio varies by [CONTACT_242138].  Therefore, the 
randomization to treatment group is stratified by [CONTACT_242139].  Depending on the 
findings  of the study, treatment re commendations might be tailored by [CONTACT_242140], and/or by [CONTACT_242141].   
 
Increased Incidence of HZ and HZO  
Herpes zoster is caused by [CONTACT_242142] (varicella), the primary 
infection caused by [CONTACT_242143].  There are about a million new cases of HZ in the US annually; up to 20% of these 
cases develop HZO, and 20 -30% of these HZO  patients develop chronic eye disease.  Although the rate of HZ 
increases with age, the number of cases peaks in individuals age 50 -59 (26).  The incidence of HZ has been 
steadily increasing in the US among people age 40 and older for unknown reasons (27).  The incidence of HZ 
in North America, Europe, and the Asia Pacific is increasing, and  this trend started in the absence of varicella 
vaccination programs against chicken pox (28).  HZ affects approximately 30% of the population, and HZO 
develops when HZ  affects the first division of cranial nerve V (29).  
 
ZEDS has the potential to have a major impact in improving outcomes and changing the standard of care of a 
common, serious chronic disease.  
 
Disease Burden  
HZ in general, and HZO in particular, can be  associated with serious complications that result in diminished 
QOL , chronic eye disease, reduced vision, and even death (30).  Most studies find that women are affected 
significantly more frequently than men with regard to HZ incidence, hospi[INVESTIGATOR_602],  and mortality (31-33).  
PHN persists for longer than 1 year in nearly half of patients older than age 70 (34-36).  The direct medical 
cost burden of HZ may exceed a billion dollars annually in the US (35).  In HZ patients who develop PHN, one -
Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  16 year costs are more than 5 times greater than costs in HZ patients without PHN (34).  The negative impact of 
HZ and PHN on health -related QOL  is closely correlated with the severity of pain and persists as long as 
clinically significant pain (37, 38). A population -based study shows that HZ is a risk factor for developi[INVESTIGATOR_242086] (39). Notably, PHN has been reported to be the most common cause of suicide in chronic pain 
patients over age 70 (40). 
 
Publications that compare HZO with HZ occurring in o ther anatomic locations point to the risk of PHN and 
stroke being greater after HZO than HZ elsewhere  (37, 41).  PHN after HZO lasts longer and is more frequent 
than PHN after HZ in general, despi[INVESTIGATOR_242087]  (36, 37, 41).  Although 
potentially fatal strokes are an uncommon complication of HZ, HZO patients have a 4.[ADDRESS_293858] ratio of stroke after HZO is 
4.3 compared to 1.3 after HZ  (42, 43) .  In a self -controlled case -series population -based study, the risk of 
stroke for 6 months more than doubled after HZO compared to HZ in general (44).  Although the risk of stroke 
after HZ is greatest in the short term, increased risk continues a fter the first year and is greatest in patients 
under age 40  (45).  
   
Approximately 30% of HZO patients treated acutely with recommended oral antivirals have ocular 
complications at 6 months compared to 50% without this treatment (46, 47) .  Patients with ocular complications 
of HZO often have a chronic disease with manifestations that vary by [CONTACT_654].  Long -term topi[INVESTIGATOR_242088].  Use of oral antivirals is 
highly variable,  with some academic cornea specialists prescribing them frequently and many ophthalmologists 
using them infrequently or not at all (24).   
 
Support for Prolonged Antiviral Therapy in HZO -associated Ocular Disease  
As documented above, the need for this large -scale trial is supported by [CONTACT_242144]; and the recent observational study (above) reporting 50% rate of 
recurrent inflammation in HZO and 35% reduc tion of recurrent disease in patients on relatively low -dose 
suppressive antiviral treatment (1).  
 
In addition, the landmark study of the long -term use of oral acyclovir for the prevention of recurrent herpes 
simplex virus (HSV) ocular disease, the Herpet ic Eye Disease Study (HEDS) Acyclovir Prevention Trial (APT), 
demonstrated a 45% reduction in recurrent ocular disease over one year  (4). It is therefore possible that in 
view of the similarities between HSV and HZO keratitis, suppressive antiviral treatme nt in HZO may reduce 
stromal keratitis and other anterior segment disease manifestations thought to be predominantly immune -
mediated, as well as dendriform epi[INVESTIGATOR_242089].  
 
Taken together, these data make a convincing case that now is the  right time to conduct this trial in order to 
obtain rigorous randomized controlled evidence to determine whether suppressing VZV infection reduces 
chronic anterior segment ocular disease and/or PHN in HZO.  
 
2.2 RATIONALE  
 
Valacyclovir is an FDA approved medication for the acute treatment of HZ, using a dose of 1000 mg three 
times a day for seven days, and for prolonged suppressive treatment of HSV genital disease in 
immunocompetent patients, using a dose of 1000 mg daily.  This study evaluates the same dose as used for 
suppression of HSV genital disease for patients with HZO, a purpose that has not been approved by [CONTACT_1622]. 
Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  17 This proposal has been reviewed by [CONTACT_242145] 
(NYUS oM). 
 
This is the first prospective multicenter placebo -controlled RCT of prolonged suppressive antiviral treatment for 
chronic HZO or HZ in immunocompetent patients.  
 
Assessment of Most Frequently Preferred Suppressive Antiviral Regimens for HZO by [CONTACT_242146] a second electronic survey conducted in 
preparation for this trial  (25).  Valacyclovir 500mg bid or 1000 mg daily was preferred by 64% (108/171).  
Valacyclovir is a prodrug of acyclovir, which has better oral absorption and bioavailability than acyclovir.  The 
peak plasma concentration of acyclovir after 500 mg of oral valacyclovir is 3.28 mcg/mL and after 1000 mg of 
valacyclovir is 5.65 mcg/mL, according to the packa ge insert.  The median inhibitory concentration of acyclovir 
to reduce VZV plaque counts by 50% (IC50) is approximately 3 mcg/mL (48).  The IC50 of acyclovir for VZV is 
higher than the IC50 of acyclovir for HSV type 1, which averages 0.45 -1.47 mcg/mL (comp ared to the peak 
plasma concentration of 1.21 mcg/mL after 400 mg acyclovir, the dose that was effective in HEDS APT) (49).  
The VZV IC50 data supports the use of valacyclovir in this study.  In order to facilitate compliance by [CONTACT_242147], [ADDRESS_293859](s) is (are) associated with the risks and discomfo rt of any blood test requiring one tube , 
equivalent to two teaspoons of blood.  
 
Risk of Study Drug Valacyclovir   
The risk related to participation in this study relates to the risk of oral antiviral treatment with valacyclovir. 
Valacyclovir is approved and recommended for acute treatment of HZ, but not for chronic treatment of HZ.  
Previous studies of long -term suppressive treatment have been done in patients with HSV disease, using a 
similar dose of valacyclovir 1000 mg daily in immunocompetent patients  (package insert).  The most common 
side effects of suppressive treatment of recurrent genital HSV infections in immunocompetent adults with 
valacyclovir 1000 mg daily include headache (35%, compared to 34% with placebo), nausea (11%, compared 
to 8% with p lacebo), and abdominal pain (11%, compared to 6% with placebo), according to the package 
insert.   Less common side effects include dysmenorrhea (8%, placebo 4%), depression (7%, placebo 5%), 
arthralgia (6%, placebo 4%), vomiting (3%, placebo 2%) and dizzin ess (4%, placebo1%).  Rates of drug 
discontinuation in prior studies are not listed.  
Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  18  
According to the package insert regarding laboratory results, hematologic abnormalities occurred in 0 -0.7% in 
adults treated with valacyclovir 1 gram daily compared to 0. 8-1.5% of adults treated with placebo.   In addition, 
AST (SGOT) liver function test abnormalities occurred in 4.1% of adults on valacyclovir 1000 mg daily, 
compared to 3.0% on placebo.  With regard to geriatric use, elderly patients age [ADDRESS_293860] to adults with liver impairment including cirrhosis, dosage modification is not recommended. Despi[INVESTIGATOR_242090], there is little evidence that oral acyclovir (valacyclovir is prodrug of acyclovir) causes 
significant liver injury, or changes in serum liver enzyme levels (http:livertox.nih.gov/acyclovir.htm) .  
Suppressive valacyclovir for HSV genital disease in immunocompetent patients at the same dose of 1000 mg 
daily and duration of one year, or longer, as used in our study has a long established safety profile with 
adverse events similar to placebo in numerou s studies, both before and after its approval in 1995 (50).  Long -
term suppressive valacyclovir was not associated with laboratory abnormalities, including creatinine levels.  
Headache, nausea, and diarrhea were the most common adverse events attributed to  the drug.  Thrombotic 
microangiopathy that has been reported at high doses (8000 mg/d) for prolonged periods for prophylaxis of 
cytomegalovirus (CMV) infection, especially in severely immunosuppressed patients, has not been reported in 
[ADDRESS_293861] will be allowed 
to restart the study medication after mild or moderate side effects resolve, if the study participant agrees.  If 
side effects recur, the dose can be reduced to one pi[INVESTIGATOR_34082], as this lower dose has been reported in a 
retrospective study to be effective in r educing recurrences in HZO (1).  
 
Valacyclovir and Renal Insufficiency  
Oral antiviral medications are generally very safe and can be used in patients with impaired renal function, but 
their dosage needs to be adjusted.  For valacyclovir, a suppressive regimen of 1000 mg daily is reduced to 500 
mg daily, in study participants with creatinine clearance < 30.  Study participants on dialysis or with a baseline 
eGFR < [ADDRESS_293862], study participants with 
eGFRs 45 -59 will be eligible, based on assessment of potential risk/benefit ratio.  Elderly patients are at 
increase d risk for and most negatively impacted by [CONTACT_242148].  Approximately 25% 
of people age [ADDRESS_293863] eGFRs between 45 and 59 (51).  Study 
participants with a baseline eGFR of [ADDRESS_293864] eGFR repeated monthly until it is 45 or more. The study participant will continue to be 
followed, but the study medication will not be restarted.  
 
The package insert contains a warning that acute renal failure can occur in the  elderly, with or without reduced 
renal function.  Nephrotoxicity is more frequent after intravenous than oral acyclovir.  Serum creatinine >1.5 of 
the upper limit of normal occurred in 0.2% of HZ patients on 1000 mg oral valacyclovir tid and 0% of genital  
HSV patients on oral valacyclovir suppression with 1000 mg daily.  Dehydration contributes to nephrotoxicity. 
Zoster Eye Disease Study (ZEDS)  Version 3.[ADDRESS_293865] to the outcome of hospi[INVESTIGATOR_21342] 30 days for acute kidney injury, 
and the risk was no higher with acyclovir and valacyclovir than famciclovir, a drug not known to be associated 
with renal toxicity (52).  In this study, acute kidney injury occurred in less than 1% of patients (0.27% of 
acyclovir or valacyclovir treated patients and 0.28% of famciclovir treated patients). Risk factors for acute 
kidney injury included higher age (patients age 85 years or olde r: 0.62% in acyclovir/valacyclovir group and 
0.71% in famciclovir group) and chronic kidney disease (1.46% in acyclovir/valacyclovir group and 1.86% in 
famciclovir group).  Acute kidney injury related to acyclovir/valacyclovir is associated with birefringe nt needle 
crystals on urinalysis.  
 
Although renal toxicity is an expected complication of valacyclovir, the frequency and severity of new or 
worsening renal disease will be monitored to determine if it is more common than expected.  Study participants 
with follow -up eGFRs less than 45, or who develop urinary symptoms, will be referred to their primary care 
doctors for evaluation, including urinalysis to detect crystals, and management.  
 
Valacyclovir and Pregnancy   
Antivirals including valacyclovir (Categor y B) are used during pregnancy only if the potential benefit outweighs 
potential risk to the fetus.   Women of reproductive age will need to agree to use a recommended form of 
contraception during the one year of study treatment, and pregnant women will be excluded by [CONTACT_242149] a menstrual cycle prior to enrollment/randomization visit. Nursing women 
will be excluded.  Study participants who become pregnant during the study will be withdrawn from the study 
medication and c ontinue to be followed .  
 
Valacyclovir and Central Nervous System (CNS) Reactions    
The package insert contains a warning that agitation, hallucinations, confusion, encephalopathy, delirium and 
seizures can occur in patients taking valacyclovir, and that elderly patients are more likely to have these 
problems.  HZO can also be complicated  infrequently by [CONTACT_242150] (CNS) vasculopathy  (stroke).   
Study participants who have CNS adverse events will have their study medicine discontinued, at least 
temporarily, and be referred for neurological evaluation and treatment.  If the trea ting physician thinks the 
safety of the study participant is an issue, the 24/7 help line is available , and, if necessary, to differentiate 
between drug and disease related CNS disease, the medical monitor can initiate the process to unmask study 
medicatio n (see Manual of Procedures, MOP).  CNS complications of HZ are thought to be rare, but may be 
under -diagnosed, and additional information regarding their frequency may be obtained in the placebo 
treatment arm of the study.  
 
Valacyclovir and Thrombotic Th rombocytopenic Purpura /Hemolytic Uremic Syndrome (TTP/HUS)   
The package insert has a warning that TTP/HUS has occurred in patients with advanced HIV disease and 
bone marrow or renal transplant recipi[INVESTIGATOR_239992] 8 grams per day of valacyclovir, a dose used for  
cytomegalovirus, not herpes zoster or simplex.   Since immunocompromise is an exclusion criterion and the 
dose of valacyclovir is much lower, 1 gram per day, TTP/HUS will be considered an unanticipated and serious 
adverse event in this study.   
 
Zoster Eye Disease Study (ZEDS)  Version 3.[ADDRESS_293866] Risk  
The investigational plan is specifically designed to manage and minimize risks through careful selection of 
study participants and suppressive antiviral treatment regimen, thorough training of study investigators and 
coordinators, adherence to the pre -determined time points to assess study participant clinical status, and 
regular clinical monitoring by [CONTACT_242151] (CC) personnel and the Data and Safety Monitoring 
Committee (DSMC). Suppressive treatment with valacyclovi r 1000 mg daily of immunocompetent individual s 
age 18 years and older is FDA approved and recommended for herpes simplex virus (HSV) genital disease.  
This study evaluates the efficacy and safety of valacyclovir, at the same dose used for HSV suppression, for 
study participants with a different diagnosis, HZO, for which valacyclovir is approved at a higher dose, for a 
short duration.  HZO patients are generally older than HSV patients, with approximately mean age of onset of 
HZO of 52 years compared to ocul ar HSV with a mean age onset of 37 years (2, 4, 53).  
  
In order to minimize risks of valacyclovir in an older population of study participants, a baseline eGFR will be 
obtained prior to enrollment. If the eGFR is [ADDRESS_293867] 
repeated monthly until it is 45 or more. The study medication will not be restarted, and the participant will 
continue to be followed  for safety assessment s.  
 
There are no known study -related risks in addition to the use of the study medication, oral valacyclovir  and 
blood testing . 
 
2.3.2  KNOWN POTENTIA L BENEFITS  
 
It is unknown whether prolonged suppressive antiviral treatment with valacyclovir reduces complications of 
HZO, including ocular disease and PHN, although oral antiviral medication is prescribed by [CONTACT_3450] 30% 
of corneal specialists according to one study, and reported effective in significantly reducing epi[INVESTIGATOR_242091] (1, 24) .  If this study determines that valacyclovir 
is effective and safe in reducing complications of HZO, study participants randomized to receive valacyclovir 
may directly benefit, as well as future HZO patients treated using this evidence.  If the study treatment is 
effective and safe in decreasing the severity, duration and frequency of PHN after HZO, this may be 
generalizabl e to HZ in other locations, and benefit many patients with PHN.  If suppressive antiviral treatment 
is ineffective or study participants receive placebo treatment, participants will not directly benefit from 
participation in this research.   If treatment is  ineffective, its current ad hoc usage in the absence of evidence 
will be reduced.  
 
[ADDRESS_293868] is to evaluate whether or not 
prolonged suppressive oral antiviral treatm ent with valacyclovir 1000 mg/daily reduces complications of HZO, 
in immunocompetent study participants , compared to treatment with placebo and standard care without 
prolonged systemic antiviral treatment, thereby [CONTACT_242152] (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  21 and life -threatening disease. Valacyclovir, a prodrug of acyclovir, has been chosen as the antiviral agent to be 
used in the trial due to its superior bioavailability.  
 
Central Hypothesis:   
Prolonged suppressive oral antiviral treatment with valacyclovir 1000 mg daily, compared to placebo, will be 
effective in reducing complications and i n improving clinical outcomes in HZO.  
 
Primary Objective :  
The primary objective is t o test the hypothesis that long -term suppressive antiviral therapy can reduce 
complications of HZO by [CONTACT_14664] a double -masked, placebo -controlled RCT of oral valacyclo vir [ADDRESS_293869] occurrence of new or worsening dendriform epi[INVESTIGATOR_242068], 
stromal keratitis, endothel ial keratitis, and/or iritis (accompanied by [CONTACT_242153]; see 
MOP) by 12 months (primary endpoint) in immunocompetent study participants  with HZO who have a history of 
one of these disease manifestations within the year prior to enrollment. The primary endpoint is measured by 
[CONTACT_242154] -specified treatment 
– see MOP . 
 
Secondary Objectives:  
The secondary objectives are:  
 to evaluate  the effect of treatment on the primary endpoint a t 18 months (6 months  after the 
completion of study drug  treatment )  
o by [CONTACT_242155][INVESTIGATOR_242068], stromal keratitis, 
endothelial keratitis, and/or  iritis in study participants  randomized  to valacyclovir versus placebo  
o by [CONTACT_242156] 18-month  period from 
randomization and  
o by [CONTACT_242157] 6-month  post treatment period .  
 to test the hypothesis that suppressive treatment for [ADDRESS_293870] herpetic neuralgia (PHN)  compared to placebo 
at 12 and 18 months in study participants with HZO.  
 to test the hypotheses that vaccination against herpes zoster with the Recombinant Zoster Vaccine 
(RZV) may impact the natural history of HZO, and that suppres sive antiviral treatment with 
valacyclovir [ADDRESS_293871], with an epi[INVESTIGATOR_242092] m epi[INVESTIGATOR_242093], stromal keratitis, endothelial keratitis, and/or iritis within one year of enrollment .  Eligible study 
participants will be randomized in a 1:1 ratio to long -term suppressive treatment with oral valacyclovir 1000 mg 
Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  22 daily or placebo for one year, and followed every 3 months for a total of 18 months, to determine outcomes of 
new or worsening anterior segment ocular disease (e.g. dendriform epi[INVESTIGATOR_242068], stromal keratitis, 
endothelial keratitis, and/or iritis) and/or severity and duration of postherpetic neuralgia during 12 months of 
treatment and for 6 months following treatment discontinuation. Within each center, p articipants will be 
randomized within four strata, defined by [CONTACT_242126] (less than 60 y ears or 60 years and greater) and 
by [CONTACT_242127] (recent onset defined as HZO diagnosed within 6 months of enrollment/  
randomization , or chronic defined as HZO diagnosed 6 months or more prior to enrollment/randomization).  
 
4.2.[ADDRESS_293872] occurrence of new or worsening epi[INVESTIGATOR_242070], stromal keratitis, endothelial keratitis, and/or  iritis due to HZO, requiring pre-specified changes in 
treatment (see MOP)  during  the twelve months of treatment.   The primary endpoint is compared for 
participants randomized to study medication or placebo.  
 
To assess the primary objectives, study participants will be monitored at each visit for new or worsening of any 
of the followin g conditions  
1. Dendriform epi[INVESTIGATOR_242068]  
2. Stromal keratitis  
a. Without ulceration  
b. With ulceration  
3. Endothelial keratitis  
4. Iritis 
The endpoint of first occurrence of new or worsening dendriform epi[INVESTIGATOR_242068], stromal keratitis, 
endothelial keratitis, and/or iritis will be determined by [CONTACT_242158]-specified changes  in 
treatment for the same disease mani festation (see MOP for definition), as there are no validated confirmatory 
biomarkers or other tests.   Primary endpoints will be reviewed by [CONTACT_242159] (CERC).  
See MOP.    
 
4.2.2 SECONDARY ENDPOIN TS 
 
To assess the secondary objectives, the study participants will be monitored at each visit for the following  
events : 
1. Time to development and number of epi[INVESTIGATOR_242094], 
stromal keratitis, endothelial keratitis, and/or iritis due to HZO , requiring pre -specified changes in 
treatment (see MOP) , during the 18 months following randomization, that includes  the 6 months 
following cessation of treatment ; and during the [ADDRESS_293873] of Recombinant Zoster Vaccine (RZV) vaccination on primary endpoints during 12 months 
of study treatment.    
 
Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  23 4. Development of specific manifestations of HZO, classified as dendriform epi[INVESTIGATOR_242068], stromal 
keratitis (all types), endothelial keratitis, iritis requiring pre -specified changes in treat ment (see 
MOP) , neurotrophic keratopathy with or without melting and/or microbial superinfection, epi[INVESTIGATOR_227], 
and/or scleritis  during the twelve months of treatment .  
5. Secondary glaucoma determined  by [CONTACT_242160].  
 
4.2.3 EXPLORATORY ENDPOINTS  
 
1. Changes in strength and/or frequency of prescribed topi[INVESTIGATOR_242095] 12 and 18 months.  
2. Occurrence of stroke  
3. Occurrence of temporal arteritis /giant cell arteritis  
4. Occurrence of myocardial infarction  
5. Occurrence of new or worsening maligna ncy 
a. Solid tumor (other than non-melanoma  skin cancer)  
b. Hematologic malignancy  
c. Lymphoma  
6. Time to development and number of epi[INVESTIGATOR_242096], 
stromal keratitis, endothelial keratitis, and/or iritis  due to HZO , with a  recent substantial reduction in 
treatment during [ADDRESS_293874] meet all of the following criteria:   
1. Ability to understand, and willingness and ability to read and sign, the informed consent form.  
2. Ability to understand and follow instructions and study procedures.  
3. Willingness to comply with all study procedures and be available for the duration of the study.  
4. Ability to take oral medication, and are willing to adhere to study m edication regimen.  
5. Age 18 years or older.  
6. Diagnosed with HZO in one eye based  on both of these criteria:  
a. History of characteristic unilateral , usually vesicular , HZO rash in the dermatomal distribution of 
cranial nerve V1  or V2 .  
b. Medical record documentation of an epi[INVESTIGATOR_242097], stromal 
keratitis, endothelial keratitis, and/or iritis due to HZO within the preceding year.  This epi[INVESTIGATOR_242098] (within the preceding 
6 months); or chronic HZO (with onset six or more months ago); may be new, worsening, or 
recurrent disease after a period of inactivity; and may occur after medication was reduced.  
i. Study participant s with chronic HZO must be on a stable treatment regimen and off antivirals 
for at least 30 days before enrollment.   Study participants with chronic HZO who do not 
meet this criterion  may be rescreened, if they are able to meet this criterion within 3 months 
after the study visit.   
Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  24 This is not a requirement for study participants with recent onset HZO, who may be 
enrolled at any time, preferably after completing recommended acute antiviral 
treatment, if prescribed, is completed.   They can be on variable dose of steroids, and  
only need to be off oral and topi[INVESTIGATOR_242099].  
7. For females with reproductive potential, willingness to use highly effective contraception (e.g., 
hormonal contraception, barrier contraception, intrauterine device, or abstinence ). 
 
5.2 PARTICIPANT EXCLUSIO N CRITERIA  
 
An individual who meets any of the following criteria will be excluded from participation in this study : 
1. History of immunocompromised status as defined by [CONTACT_242161]  (44). 
a. Study participants who are diagnosed with leukemia, lymphomas or other malignant neoplasms 
affecting bone marrow or lymphatic system, unless leukemia in remission and off chemotherapy 
for at least 3 months.  
b. Study particip ants who are diagnosed with Acquired Immune Deficiency Syndrome ( AIDS ) or 
presents with  other clinical manifestations of  Human Immunodeficiency virus  (HIV) including 
CD4 count of ≤ 200 cells/ ml. 
c. Study participants on immunosuppressive therapy including:  
i. High-dose corticosteroids (greater than equivalent of prednisone 20 mg/day within 1 month)  
ii. Chemotherapy, other than low dose used for treatment of immune -mediated diseases 
within [ADDRESS_293875] emic disease and thought likely to meet one of the exclusion criteria listed 
in exclusion criteri on #1 during the 18 -month study period.  
3. Renal insufficiency:  
a. Requires dialysis or has history of renal transplant or  
b. eGFR less than 45, determined within [ADDRESS_293876] zoster within one month  prior to enrollment .  Study participants who 
meet this exclusion criterion may be screened and enroll ment  delayed until eligible  within 3 months .  
If the study participant receives the Herpes Zoster Subunit vaccine  (Recombinant Zoster Vaccine 
(RZV), Shi ngrix), rescreening should  take place one month after the second required dose of the 
vaccine.  
6. Keratorefractive surgery, other than limbal relaxing incisions or astigmatic keratotomies at the time 
of cataract surgery, within [ADDRESS_293877] 30 days, including acyclovir, 
valacyclovir, or famciclovir, for any reason except for treatment of recent onset  HZO, including 
investigational drug trial . 
8. History of another condition that may require treatment with one of these three antivi rals listed 
above in  exclusion criter ion #7, during the course of the study; study participants who require 
chronic suppressive antiviral treatment with these medications will be excluded.  
Zoster Eye Disease Study (ZEDS)  Version 3.[ADDRESS_293878] his/her full compliance or completion of the study.  
12. Participation in a clinical study testing a drug, biologic, device or other intervention within the last [ADDRESS_293879] (IRB) registered  with the US Office for Human Research 
Protections (OHRP) under a Federal Wide Assurance (FWA)  for review and approval .  
 
Eligible study participants will be identified by [CONTACT_242162] (PCC)  by [CONTACT_242163]  (e.g. computerized search of HZO diagnostic codes) and prospective methods  
(e.g. advertising, referrals from other doctors) .   All recruitment methods , advertising  and materials will be 
submitted to responsible IRBs prior to release.  Potential study participants may be contact[CONTACT_242164]. Pre -screening interview questionnaires  and screening logs  to assess 
patient eligibility and interest, together with materials to be used for collection of patient information p rior to  the 
consenting process will be submitted to responsible IRBs for review and approval. ( See MOP for recruitment 
and retention strategies .)  
 
5.[ADDRESS_293880] occurrence of new or worsening dendriform epi[INVESTIGATOR_242068], stromal keratitis, endothelial keratitis, 
and/or iritis, or discontinue the study medication.  Every effort will be made to collect this follow up information. 
Study participants who withdraw without an event will be considered censored in the analyses.  
 
A study participant may be withdrawn , if, the study investigator determines that an event  or medical condition  
has occurred  that would make continued study participation not in the best interest of the study participant .   
 
Efforts will be made to refer study participants to another PCC if they move or are away at the time of study 
visits.  All ef forts should be made to locate or communicate with study participants who have missed study 
visits. (e.g. contact [CONTACT_107461], written communication, text, email, through participant’s family, friends or 
healthcare proxy which were provided by [CONTACT_242165], to determine if outcome events have 
occurred.)  
 
 
Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  26 5.5 PREMATURE TERMINATIO N OR SUSPENSION OF S TUDY  
 
This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable cause. 
Written notification, documenting  the reason for study suspension or termination, will be provided by [CONTACT_242166] , funding agency, the IND sponsor and the FDA .  If the study 
is prematurely terminated or suspended, the study chair will promptly in form the IRB  and the PCC  principal  
investigators, and will provide the reason(s) for the termination or suspension. Circumstances that may warrant 
termination or suspension include, but are not limited to:    
 
 Determination of unexpected, significant, or un acceptable risk to participants  
 Demonstration of efficacy that would warrant stoppi[INVESTIGATOR_007]  
 Insufficient compliance to protocol requirements  
 Data that are not sufficiently complete and/or evaluable  
 Determination of futility  
 
The s tudy may resume once concerns ab out safety, protocol compliance, data quality are addressed and 
satisfy the sponsor, IRB and/or FDA.  
 
6 STUDY AGENT  
 
6.1 STUDY AGENT (S) AND CONTROL DESCRIPTION  
 
6.1.[ADDRESS_293881] them sent  to a 
drug manufacturer  for over encapsulation . An over encapsulated matching pi[INVESTIGATOR_242100] p lacebo  pi[INVESTIGATOR_4382].  Both active and placebo pi[INVESTIGATOR_3353] w ill 
be se nt to a Drug Distribution Center ( DDC ). The D DC will receive, store, and dispense  study medication  to 
PCCs .  Upon receipt of the of the study treatment supplies in individually labeled bottles at the PCC, drug 
handling and accountability procedures must be followed (see MOP).    At the time of randomization, the 
appropriate drug supply will be dispensed to study participant s.  The study medication is dispensed only  after 
eligibility is confirmed and study participant age at onset of HZO and  duration of HZO at time of enrollment/  
randomization is provided to the Electronic Data Capture web -based interactive computer system.  At the 3, 6, 
9, and 12 -month follow -up visit, unused pi[INVESTIGATOR_242101] .  Unused drug will 
be returned to the ZEDS CC  for disposal ; PCCs can dispose of the unused drug on site if they have a policy 
compliant with applicable regulations . 
There will be reconciliation of drug shipped, drug consumed, and drug remaining  at each PCC  as specified in 
the MOP .  
 
 
 
Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  27  
6.1.2  FORMULATION, APPEARANCE , PACKAGING, AND LABEL ING 
 
Valacyclovir was approved for the treatment of HSV and HZ in 1995, and has been  available as a generic drug 
since 2009 . (See MOP and MOP appendix: FDA package label for drug information ).  Generic s tudy drug will 
be purchased from a manufacturer . 
 
The drug manufacturer will deliver the study drugs to a DDC. The DDC will label and distribute the study 
medication to the PCCs  as directed by [CONTACT_242167]. The DDC will repackage the masked study 
medication  (active or placebo)  into bottles with child-resistant caps and tamper -foil seals.  
 
Study participants will be given a sufficient  supply of encapsulated study medication in labeled  bottles at the 
enrollment, 3, 6, and 9 -month follow -up visits.   Each bottle of study medication will be labeled to ensure 
masking and provision of study medication in accordance with randomization assignment . The study label will 
also state the expi[INVESTIGATOR_78288].  (See MOP)  
 
6.1.[ADDRESS_293882] STORAG E AND STABILITY  
 
The study medication is to be stored at room temperature 15 to 25 °C (59 to 77 °F) in a  secure location (e.g.  
locked cabinet , restricted access pharmacy)  accessible only to designated staff at the PCC  (see MOP for drug 
storage, drug stability, expi[INVESTIGATOR_242102], or instructions for when bottle seal is broken ). 
 
6.1.4  PREPARATION  
 
No further preparation of the study medication is required  by [CONTACT_242168] . 
 
6.1.5  DOSING AND ADMINISTRATION  
 
Eligible study participants will be randomized in a 1:1 ratio to suppressive treatment with oral valacyclovir 1000 
mg daily or placebo for one year .  Study pa rticipants will be followed every 3 months for a total of 18 months , 6 
months foll owing completion of the 12-month  treatment period .  Study participants will be instructed to take 2 
pi[INVESTIGATOR_242103] .   
 
6.1.6  ROUTE OF ADMIN ISTRATION  
 
Study medication will be taken by [CONTACT_242169].  
 
6.1.7  STARTING DOSE  AND DOSE ESCALATION  SCHEDULE  
 
The starting dose of valac yclovir is 1000mg daily. There is no dose escalation.  
 
6.1.8 DOSE ADJUSTMENTS/MOD IFICATIONS/DELAYS  
Study investigators will be trained and study participants will be instructed regarding dose adjustments of study 
medication.  
Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  28 Use of Divided Dose of Study Medication for Intolerance  
If the study participant has mild to moderate side effects to the study medication, the medication may be 
temporarily discontinued .  The study participant may take one pi[INVESTIGATOR_242104], instead of two pi[INVESTIGATOR_242103], as 
it may be better tolerated.  
 
Use o f Reduced Dose of Study Medication for Intolerance  
If the study participant has mild to moderate side effects to the study medicine when taken in divided doses, 
the medication may be temporarily discontinued .  The study participant may take a reduced dose of one 
capsule daily.  
 
Discontinuation of Study Medication due to Intolerance  
If intolerance to the study medication is moderate or worse after restarting the study medication in divided 
doses and reducing the dose, the study medication will be permanentl y discontinued. The study participant will 
be treated at the discretion of ophthalmologists involved in their care, and continue to be followed.  Open label 
use of other antivirals after study medication is discontinued will be collected and monitored . 
 
Discontinuation of Study Medication  
If the study participant develops a contraindication to valacyclovir during the course of the study (See 5.2.).The 
study medication will be permanently discontinued and the study participant will continue to be followed.    
 
Discontinuation due to Pregnancy  
 
If a study participant becomes pregnant , the study medication will be discontinued  and the study participant will 
continue to be followed . If a study participant thinks she may be pregnant, a pregnancy test will be per formed.  
 
Discontinuation due to Worsening Chronic Kidney Disease  
 
If a study participant develops worsening chronic kidney disease with confirmed eGFR less than 45, the study 
medication will be discontinued and the study participant will continue to be followed.  
 
Discontinuation due to Acute Kidney Failure  
 
If a study participant develops acute kidney failure , and requires temporary or permanent dialysis , the study 
medication will be discontinued  and the study participant will continue to be followed .  
 
Temporary Discontinuation due to Vaccination Against Zoster  
 
If the study participant decides to get the Zoster Vaccine  Live (ZVL ),Zostavax , manufactured by [CONTACT_44873])  against 
zoster, the study medication will be discontinued one day before and resumed one month after vaccination.   If 
the study participant gets the Reco mbinant Zoster Vaccine (RZV), also referred to as the herpes zoster subunit 
vaccine  (Shingrix manufactured by [CONTACT_242170]), the study medication is  to be  continued. As of 
January, 2018 the CDC recommends the RZV as preferred over ZVL.  
 
Temporary or Permanent Discontinuation due to Use of Open Label Oral Valacyclovir, Acyclovir or 
Famc iclovir Treatment for Other Conditions  
Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  29  If the study participant develops ocular, orofacial , or genital HSV disease and requires a short term 
(maximum two weeks) cour se of oral antiviral treatment, the study medication will be temporarily 
discontinued during this treatment, and resumed afterwards. If the study participant requires long -
term antiviral treatment for HSV, the study medication will be permanently discontin ued, the 
participant will continue to be followed in the study, and the study medication will not be unmasked.  
 If study participant develops HZ in another anatomical location, study medication will be 
discontinued, the participant will be given recommende d acute antiviral treatment for 7 days, and 
then the study medication will be resumed.  
 If study participant is diagnosed with central nervous system disease  (including stroke)  due to 
zoster , study medication will be discontinued while participant receives intravenous antiviral 
treatment, sometimes followed by a course of oral antiviral treatment, and resumed afterwards, if 
the treating neurologist agrees. The study participant will continue to be followed in the study.  
 If study participant develops any othe r medical condition that necessitates treatment with 
valacyclovir,  acyclovir, or famciclovir , the study medication will be  discontinued  while on open label 
treatment and resumed afterwards ,. The open  label treatment period should not usually exceed two 
weeks.  
 
Temporary Discontinuation due to Short -term (maximum two weeks) Open Label Use of Valacyclovir, 
Acyclovir or Famciclovir  for HZO  
If the study participant develops a possible  primary endpoint - new or worsening dendriform epi[INVESTIGATOR_242068], 
stromal keratitis, endothelial keratitis, and/or iritis - and the study investigator thinks the study participant may 
benefit from a one to two -week course of open label oral antiviral treatment, the study medication will be 
temporarily discontinued, and resumed when the course of open label treatment is completed.  (After a study 
participant develops a possible  primary endpoint, if topi[INVESTIGATOR_242105], the study 
medication is continued.)  
 
Permanent Discontinuation due to Prolonged Open Label Use of Valacyclovir, Acyclovir or Famciclovir  
for HZO  
If the study participant develops a poss ible primary endpoint - new or worsening dendriform epi[INVESTIGATOR_242068], 
stromal keratitis, endothelial keratitis, and/or iritis - and the study investigator thinks the participant may benefit 
from prolonged open label antiviral treatment, the study medic ation will be discontinued, and the participant will 
continue to be followed.  Any open label use of antivirals will be collected and centrally monitored.  
 
6.1.9 DURATION OF THERAPY  
 
The duration of therapy is one year  (12 months)  from study enrollment/randomization.   All study participants  
randomized will be included in the analyses of the primary efficacy endpoint in this intent to treat trial.      
 
6.1.[ADDRESS_293883] s will be provided to study participants to enhance compliance (see MOP).  
The importance of compliance will be included on the participant instruction sheet and will be discussed at 
each study visit during the one year of treatment by [CONTACT_242171]  (see MOP).   
 
Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  30 6.1.1 1 DEVICE SPECIFIC CONS IDERATIONS  
 
Not applicable.  
 
6.2 STUDY AGENT ACCOUNTA BILITY PROCEDURES  
 
Study medication will be sent to the PCCs by [CONTACT_242172].  Designated  study  staff at the 
PCCs will distribute the  medication to participants at Visits 2, 3, 4, and 5, and will be required to complete  
relevant drug accountability documents (see MOP) .  Study pa rticipants will  be asked to  return the medication 
bottles and any unused medication at study vis its 3, 4, 5 and 6 . 
 
7 STUDY P ROCEDURES AND SCHEDULE  
 
7.1 STUDY PROCEDURES /EVALUATIONS  
 
7.1.1  STUDY SPECIFIC  PROCEDURES  
  
The following procedures will be performed for study -specific purposes:  
 Review of inclusion/exclusion  criteria  for eligibility  
 Informed consent  
 Collection of demographic information  
 eGFR and Pregnancy Tests  
 Collection of HZO treatment information  
 Randomization: Eligible participants will be randomized to receive either valacyclovir or matching 
placebo.  
 Study specific history: asse ssment of post herpetic neuralgia using question #3 of Zoster Brief Pain 
Inventory (ZBPI)  
 Study specific ophthalmic exam  of the eye with HZO  
 Completion of medical event form  
 Collection of information regarding any serious adverse events ( SAEs ) 
 Assessment o f study adherence :  counts  of returned unused pi[INVESTIGATOR_242106] . 
 Monthly contact [CONTACT_242173], eg. telephone, email, text,  or letter  is encouraged .  (See 
MOP)  
 
7.1.[ADDRESS_293884] of care:  
 
 History  and exam  of zoster eye unrelated to zoster  
 History and exam of the non -zoster eye 
 History and exam at visit s other than required study visits  
 
Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  31 7.2 LABORATORY PROCE DURES/EVALUATIONS  
 
7.2.1 CLINICAL LABORATORY EVALUATIONS  
 
The following laboratory procedures/evaluations will be performed  at the study participant’s closest study 
designated d iagnostics laboratory , or local laboratory when necessary : 
 
 Blood test for eGFR  prior to enrollment : All study participants will be asked to obtain a serum 
creatinine blood  test for eGFR determination. Measurement of creatinine to calculate eGFR will not 
be required if it has been completed in the past [ADDRESS_293885] of care.  
 Blood test for pregna ncy prior to enrollment :  Women of childbearing potential will be asked to take 
a pregnancy test. During the study, women who are able to become pregnant must agree to use a 
medically accepted method of birth control, including hormonal methods, barrier method, 
intrauterine device, or abstinence, while on the study drug.  This is a study -specific procedure and is 
not standard of care.  
 Urinalysis: For study participants with acute kidney disease to look for crystals associated with 
valacyclovir.  
 A urine dip stick test for pregnancy will be conducted by [CONTACT_242174] a study participant 
suspects pregnancy at the time of a study visit.  
 
7.2.2 OTHER ASSAYS OR PROCEDURES  
 
Not applicable.  
 
7.2.3 SPECIMEN PREPAR ATION, HANDLING, AND  STORAGE  
 
Not applicable.  
 
7.2.4 SPECIMEN SHIPME NT 
 
Not applicable.  
 
7.3 STUDY SCHEDULE  
 
7.3.1  SCREENING /CONSENT   
 
HZO patients who are thought likely to be eligible for the study on the basis of an eligibility checklist and review 
of their medical records by [CONTACT_63789]/or coordinator will have a screening visit. The following 
will be performed/obtained:  
 
 The consent f orm will be reviewed and signed .  
Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  32  Study specific review of medical records .  
 Study specific review of demographics . 
 Review of study inclusion/exclusion  criteria . 
 Blood test for eGFR  ordered.  
 Blood test for pregnancy order for women of child bearing potential   
Measurement of creatinine to calculate eGFR will be ordered within [ADDRESS_293886] agree to use a medically accepted method of birth control, 
including hormonal methods, barrier method, intrauterine device, or abstinence, while on the study drug.  
 
7.3.2  ENROLLMENT/ RANDOMIZATION   
 
At the enrollment/randomization visit, the following will be performed/obtained:  
 
 Study specific history of HZO treatment .  
 Study specific ophthalmic exam, including: routine visual acuity and manifest refraction, (not 
standardized or by [CONTACT_242175]) ant erior segment ophthalmic exam, measurement of corneal 
thickness, dilated fundus exam and pachymetry of study eye.  
 Study specific review of inclusion/exclusion criteria . 
 Study specific post herpetic neuralgia score and review of medication  history for PHN . 
 Randomization: Study participants who have provided written consent and meet study entry criteria 
will be randomized within center to one of the four strata depending on their age at the onset  of 
HZO (age less than 60 years compared to 60 or older) and duration of HZO at the time of 
enrollment and randomization  (less than 6 months compared to greater than or equal to 6 months).  
 Study participants will be dispensed a n adequate supply of study me dication consistent with 
randomization assignment and will receive i nstructions to take 2 pi[INVESTIGATOR_242103], in addition to any 
other medication(s)  (See MOP) . 
 Study participants will receive instructions to maintain adequate hydration to decrease the likeli hood 
of nephrotoxicity (See MOP) . 
 Study participants will a diary to record when study medication  is taken . 
 If the baseline eGFR was 45 -59, the study participant will be given a prescription for repeat testing 
prior to their next visit.  
 An appointment to return during a specified window of days for their three -month follow -up visit  will 
be scheduled .  
 
The importance of compliance with the study medication and visits will be emphasized . Study participant’s 
contact [CONTACT_242176] (see MOP).   
 
Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  33 7.3.3  FOLLOW -UP STUDY VISITS   
 
Study v isit number  at 3, 4, 5 occurring at months 3, 6, and 9 after enrollment:   
At the follow -up visits, the following activities will occur/be performed:  
 
 Study specific history of HZO treatment.  
 Study specific anterior segment ophthalmic exam.  
 Assessment of post herpetic neuralgia score and  review of  medications  taken for  PHN . 
 Returned study medication pi[INVESTIGATOR_242107].   Diaries will be 
returned.  
 Assessment for  possible medical event s of interest  
 Assessment for possible primary endpoints.  
 Assessment for possible SAEs . 
 Study participants will be dispensed an adequate  supply of study medication and will receive 
instructions to take 2 pi[INVESTIGATOR_242103] . in addition to any other medication(s).  At the discretion of the 
investigator, dosage may be adjusted to one pi[INVESTIGATOR_242108] (see MOP).  
 Study participants will receive a diary  to record when study medication  is taken . 
 If the s tudy participant  had a baseline eGFR of 45 -59 repeat eGFRs will be completed prior to the 3, 
6, 9 month study visits.  
o If eGFR is 45 or above, study medication will be continued.  
o If eGFR is less than 45, the study medication will be discontinued , and the eGFR will be 
repeated  within one week . If on repeat testing  the eGFR : 
 is 45 or more , the study medication will be resumed , and eGFR will be repeated within 30 
days of the next study visit .  
 is less than 45, study participant will be given a prescription to visit their local study 
designated laboratory for monthly eGFR testing until it is 45 or more. In addition,  study 
participants will be told  to see their primary care doctor for management of their kidney 
disease. The study medication will not be resumed, and the study participant will continue to 
be followed in the study.  
 An appointment to return during a specified window of days for their t hree-month follow -up visit  will 
be scheduled .  
 The study participant will be instructed to continue their non -study treatment.   
 
The importance of compliance with the study medication and visits, will be emphasized at each study visit. 
Study participant’s  contact [CONTACT_242176] (see MOP).  
 
Visit 6 (12 month follow -up visit) : 
 
At this visit, study medication will be discontinued. The visit will be the same as the 3, 6, and 9 - month follow -
up visits, with the addition  of: 
 
 Study specific ophthalmic exam including d irect fundus exam . If visual acuity  is 2 or more lines 
lower than enrollment visual acuity , then a routine refraction will be done in the study eye. If visual 
acuity  is not improved by a routine refraction , then a dilated fundus will be performed.  
Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  34  In study participants with enrollment eGFR [ADDRESS_293887] will be done prior to this visit : 
 if 45 or above, will not be repeated (this is not part of routine care).  
 If less than 45, eGFR will be repeated  within one week . If on repeat testing  the eGFR : 
o is 45 or more , it will not be repeated.  
o is less than 45, study participants will be given a prescription to visit their local study designated 
laboratory for monthly eGFR testing until it is 45 or more. In addition study participants will be 
told to see their primary care doctor for management of their kidney disease , and the study 
participant will continue to be followed .   
 The study participant will be instructed to continue their non -study treatment.   
 
Visit 7 (15 month follow -up visit ):  
 
The visit will be the same as the 3, 6, and 9 - month follow -up visits (please note there is no study medication 
involved  and eGFR testing is not repeated  (see MOP) .  
 
7.3.4  FINAL STUDY VISIT  
 
Visit 8 (18 month final study visit)  
 
The visit is the same as the 15  month  follow -up visit (Visit 7). This visit is the last study visit for the participant 
and the study completion form will be filled out  (see MOP) .  
 
7.3.5 EARLY TERMINATION VISIT  
 
This visit is similar to the 18-month visit  (See MOP) . 
 
7.3.6  NON -STUDY VISIT ( UNSCHEDULED /SCHEDULED VISIT ) 
 
At non -study visits, a standard office medical exam will be completed (routine care)  (See MOP) .  A CRF for 
non-study visit will be completed by [CONTACT_5984].  Additional CRFs may be required if a primary endpoint 
may have occurred at the time of the non -study visit.   
 
7.3.[ADDRESS_293888] and 
evaluate the clinical  trial.  Study monitors will compare data entered in electronic CRF’s to information in 
source document s to verify the accuracy of trial data.    
 
Please see Table 1  for Schedule of Events . 
 
 
 
 
 
 
Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  35 Table 1:  Schedule of Events .   
 

Zoster Eye Disease Study (ZEDS)  Version 3.[ADDRESS_293889] treatment.  It is the purpose of this study to evaluate the 
efficacy of prolonged suppressive antiviral treatment, to determine whether it should become optimal medical 
therapy in the future.  Aside from the antiviral  medications valacyclovir, acyclovir, and famciclovir , all other 
concomitant systemic medications are allowed during the study. Study participants who require topi[INVESTIGATOR_242109] 1% or lotep rednol 0.5% at the discretion 
of their study investigator. Study participants who develop dendriform epi[INVESTIGATOR_242110] (0.15%) five times daily until healed and then two times daily for two 
week s.  These topi[INVESTIGATOR_242111] s are standard  care.  
 
7.5.1 PRECAUTIONARY MED ICATIONS, TREATMENTS , AND PROCEDURES  
 
Not applicable.  
 
7.6 PROHIBITED MEDIC ATIONS, TREATMENTS, AND PROCEDURES  
 
Until a possible primary outcome is reached open label treatment of HZO eye disease with oral valacyclovir, 
acyclovir, or famciclovir is prohibited for duration of the study (i.e. 18 months).  
 
7.[ADDRESS_293890] 
and treated at their physician’s discretion.  
Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  37  
8 ASSESSMENT OF SAFET Y 
 
8.1 SPECIFICATION OF SAFETY PARAMETERS  
 
It is the responsibility of the PCC Principal Investigator (PI) to oversee the safety of the study at his/her center. 
This safety monitoring will include trainin g, careful assessment and appropriate reporting of serious adverse 
events  (see MOP) . 
 
The CC monitoring of serious adverse  events will be reviewed  by [CONTACT_242177]. These medical 
monitors will also have the ability to unmask treatment if required  in an emergenc y for study participant safety 
(see MOP) . 
 
At each contact [CONTACT_230188], the PCC study investigator or designated study team  member will 
assess for possible medical events of interest, possible primary endpoints and for possible SAEs  (see MOP) .  
 
8.1.[ADDRESS_293891] ED ADVERSE EVENTS (AE)  
 
Adverse events that result in temporary or permanent discontinuation of study medication will be required to be 
reported by [CONTACT_242178] .  
 
8.1.2 DEFINITION OF S ERIOUS ADVERSE EVENT S (SAE)  
  
Serious, unexpected adverse events related to  the study treatment will be primary safety endpoints. A serious 
adverse event is any untoward occurrence that:  
 
 Results in death.  
 Is life threatening; (a nonlife -threatening event which, had it been more severe, might have become 
life-threatening, is not necessarily considered a serious adverse event).  
 Requires inpatient hospi[INVESTIGATOR_1081].  
 Results in persistent or significant disability/incapacity or substantial disruption of the ability to 
conduct normal life func tions.  
 Is a congenital anomaly or birth defect.  
 Is considered a significant medical event by [CONTACT_242179] (e.g., 
may jeopardize the study participant or may require medical/surgical intervention to prevent one of 
the out comes listed above).  
 The occurrence of the SAE acute kidney failure , defined as requiring temporary or permanent 
dialysis,  will be a safety endpoint.  
 
8.1.3 DEFINITION OF UNANTI CIPATED  (UNEXPECTED)  PROBLEMS   
 
OHRP considers unanticipated problems involving risks to participants or others to include, in general, any 
incident, experience, or outcome that meets all of the following criteria:  
 
Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  38  Unexpected in terms of nature, severity, or frequency given (a) the research procedures that are 
described in the protocol -related documents, such as the IRB -approved research protocol and 
informed consent document; and (b) the characteristics of the parti cipant population being studied;  
 Related or possibly related to participation in the research (“possibly related” means there is a 
reasonable possibility that the incident, experience, or outcome may have been caused by [CONTACT_242180] i nvolved in the rese arch) . 
 Suggests that the research places participants or others at a greater risk of harm (including 
physical, psychological, economic, or social harm) than was previously known or recognized.  
 
This study will use the OHRP definition of unexpected/unantic ipated  problems .  
 
The determination that a  serious adverse event is related to the study treatment is initially made by [CONTACT_31821] , reviewed by [CONTACT_242181] . 
 
8.2 CLASSIFICATION OF AN ADVERSE EVENT  
 
8.2.1 SEVERITY OF EVENT  
 
Events that result in temporary or permanent discontinuation of study medication will be  recorded on 
appropriate study eCRF  (See MOP) .  
 
The intensity (or severity) of events will be rated on a three -point scale:  
 Mild: Events that require minimal or no treatment and do not interfere with the participant’s daily 
activities.  
 Moderate : Events  that result in a low level or inconvenience or concern with the therapeutic 
measures. Moderate events may cause some interference with functionin g. Mild or moderates side 
effects to study medication may result in temporary or permanent discontinuation without being a 
serious adverse event.  
 Severe:  Events  that interrupt a participant’s usual daily activity and may require systemic drug 
therapy or other treatment. Severe events are usually potentially life -threatening or incapacitating.  
 
It is emphasized that the term severe is a measure of intensity: thus, a severe adverse event is not necessarily 
serious. For example, itching for several days may be rated as severe, but may not be clinically serious.  
 
8.2.[ADDRESS_293892] been caused by [CONTACT_8235]. To ensure consistency of AE/SAE causality 
assessments, study investigators should apply the following general guid eline when determining whether an 
AE/SAE  is related:  
 
 Related :  There is a plausible temporal relationship between the onset of the event and 
administration of the study treatment, and the event cannot be readily explained by [CONTACT_2299]’s 
clinical sta te, intercurrent illness, or concomitant therapi[INVESTIGATOR_014]; and/or the event  follows a known pattern 
Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  39 of response to the study treatment; and/or the event abates or resolves upon discontinuation of the 
study treatment or dose reduction and, if applicable, reappears  upon re -challenge.  
 Not related :  Evidence exists that the event  has an etiology other than the study treatment (e.g., 
preexisting medical condition, underlying disease, intercurrent illness, or concomitant medication); 
and/or the event  has no plausible te mporal relationship to study treatment administration (e.g., 
cancer diagnosed [ADDRESS_293893] dose of study drug) ; and/or an alternate etiology has been 
established . 
 
If necessary, the PCC PI [INVESTIGATOR_242112]/SAE.  
 
8.2.3 EXPECTEDNESS  
 
The PCC  PIs will be responsible for determining whether of any serious adverse event or adverse events that 
lead to discontinuation of study medication  is expected or unexpected.  An AE/SAE will be consid ered 
unexpected if the nature, severity, or frequency of the event is not consistent with the risk information 
previously described for the study agent  in the package insert .  If necessary, the PCC  PI [INVESTIGATOR_242113]/SAE. 
 
8.3 TIME PERIOD AND FREQ UENCY FOR EVENT ASSE SSMENT AND FOLLOW -UP 
 
Serious a dverse events  (SAEs)  occurring during the study period must be recorded.  SAEs  that are related to 
the study medication that are still ongoing at the end of the study period must be followed up to determine the 
final outcome.  SAEs  that occur within 30 days after study drug discontinuation will occur within the period of 
long-term follow -up as specified by [CONTACT_760].  SAEs  will be reported on a SAE form in the EDC system  (see 
MOP) . 
 
8.4 REPORTING PROCEDURES  
 
8.4.1 ADVERSE EVENT REPORT ING  
 
Each PCC PI [INVESTIGATOR_242114]’s 
Institutional Review Board or the central IRB.  
 
8.4.[ADDRESS_293894] the CC.   CC staff will report these events to the applicable regulatory 
authorities within the required timelines  (see MOP  for details ). 
 
Unexpected, related SAEs  are reviewed by [CONTACT_242182]. These and a ll other  reported SAEs  are reviewed by [CONTACT_6802].  MedDRA coding conventions will be 
used.  The CC will notify all PCC PIs of the DSMC findings and recom mendations.   
Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  40   
8.4.3 UNEXPECTED/ UNANTICIPATED PROBLE M REPORTING  
 
Incidents or events that meet the OHRP criteria for unexpected/ unanticipated problems require the notification 
of the CC. It is the site investigator’s responsibility to report unexpected/ unanticipated problems s to their IRB 
and to the CC.  
 
To satisfy the requirement for prompt reporting, unexpected/ unanticipated problems will be reported using the 
following timeline:  
 unexpected/unanticipated problems  that are SAEs will be reported to the CC within 24 hours of the 
investigator becoming aware of the event.  
 It is the PCC PI’s responsibility to notify institutional officials and/or the IRB of unexpected/ 
unanticipated problems that are SAEs, as required.  
 
8.4.[ADDRESS_293895] is positive the study medication will 
be stopped permanently ; the study participant will be referred to see her doctor and will continue to be followed 
by [CONTACT_5984]. The study investigator will notify their PCC PI [INVESTIGATOR_242115] (7) days. The CC will notify the DSMC and FDA within fifteen (15) days.  
 
The study investigator will  have permission to follow the pregnant study participant to determine pregnancy 
outcome.  
 
8.5 STUDY HALTING RULES  
 
A formal interim analysis is proposed and is described in the SAP.  In addition, a continuous sequential safety 
stoppi[INVESTIGATOR_242116] .  In this study, the predominant 
safety concern is acute kidney failure .  The DSMC may recommend halting the study for safety, efficacy or 
other reasons (SAP) . 
 
8.6 SAFETY OVERSIGHT  
 
A DSMC has been  appointed by [CONTACT_242183] (NEI) to monitor safety unmasked to treatment at 
regular intervals (at least once/6months).  
 
Safety oversight will be under the direction of the DSMC  that is composed of individuals with the appropriate 
expertise, including ophthalmology , statistics, clinical trials and ethics.  The DSMC will meet at least 
semiannually to assess safety and efficacy data on each group of the study.  The DMSC will operate under t he 
Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  41 rules of an approved charter that outlines the operating guidelines for the committee and the procedures for the 
interim evaluations of study data and will be written and reviewed at the organizational meeting of the DSMC. 
At this time, each data elemen t that the DSMC needs to assess will be clearly defined.   The DSMC will provide 
advice  to NEI.  The DSMC will monitor study participant safety and review performance of the trial. Reports wil l 
be prepared regularly in accordance with the plan outlined in t he charter and as requested by [CONTACT_16676], 
and will include interim analysis(es) of primary and secondary endpoints; additional safety events; and other 
information as requested by [CONTACT_942].  After each meeting, the DSMC will give advice  to the NE I about 
the continuation of the study.  After approval by [CONTACT_173014], a summary of the DSMC report and recommendatio ns 
will be forwarded by [CONTACT_242184], as applicable.  
DSMC reports will be the primary mechanism for reporting safety concerns to NEI and IRBs.  
 
Sequential safety procedures (54) for life -threatening conditions in clinical trials will be employed. The 
unmasked study statistician s will be responsible for the oversight and implementati on of this plan. Results will 
be provided to the DSMC.   
 
If study participant safety requires unmasking, such as in the event of overdose of study medication, 
unmasking will be available through a [ADDRESS_293896] of the trial is in compliance with 
the currently approved protocol/ amendment(s), with GCP, and with applicable regulatory requirement(s).  
Monitoring for this study will be performed by [CONTACT_242185].  
 
The CC is the first line of contact [CONTACT_242186], f orms, procedures, quality, monitoring, and other study components, ensuring PCC understanding 
and operationalization of the protocol, and successful identification of eligible patients for screening and 
enrollment, protocol adherence and study participant retention.  Substantial written correspondence and logs of 
phone conversations will be filed within the ZEDS mailbox.  All IRB related correspondence will be filed in the 
PCC ’s file within the ZEDS Trial Master File (TMF).   
 
Study recruitment, enrollment, and retention are monitored based on reports generated by [CONTACT_242187].  Study screening information is reviewed by [CONTACT_242188] t, assisting with potential strategies to improve study enrollment. The 
ratio of screened to randomized participants is also reviewed.  Enrollment and visit attendance is also 
monitored on an ongoing basis by [CONTACT_3445], by [CONTACT_242189], and for the overall study.  
   
Data performance indicators for each PCC and for the overall study are also reviewed. These include CRF -
level and field -level completeness, data accuracy, data entry timeliness, query  resolution timeliness . Essential 
protocol adherence requirements are  also monitored from the database.  Important components of adherence 
monitoring include ensuring that informed consents are signed  and dated by [CONTACT_2299] , confirming that 
study participants are re -consented in accordance with protocol specifications  (if needed), and making sure 
that inclusion and exclusion criteria are met.  PCCs with s tudy participants who have  excessive missed  study 
visits, as well as data collected outside the permitted visit windows are identified, and participants who are not 
Zoster Eye Disease Study (ZEDS)  Version 3.[ADDRESS_293897] access to electronic medica l records (EMR)  and to electronic data 
capture (EDC).   If additional centers are added similar information will be obtained.  
 
The CC will ensure the training of monitoring personnel prior to initiation of study enrollment and as specified in 
MOP to ensure the monitoring plan is executed. This will include but not be limited to training of monitors on 
specific protocol requirement s, monitoring plans, and standard operating procedures.  
  
Details of PCC  monitoring are documented in a Clinical Monitoring Plan (CMP). The CMP describes in detail 
who will conduct the monitoring, frequency of monitoring will be done, at what level of det ail monitoring will be 
performed, and the distribution of monitoring reports.  
  
10 STATISTICAL CONSIDER ATIONS   
 
10.1 STATISTICAL ANALYSIS  PLAN  
 
A Statistical Analysis Plan provide s a complete description of all statistical considerations  and analysis plans  
(see SAP ). 
 
10.[ADDRESS_293898] occurrence of new or 
worsening anterior segment ocular disease ( dendriform epi[INVESTIGATOR_242068], stromal keratitis, endothelial keratitis, 
and/or iritis ) compared to placebo by 12 months.   
 
The secondary objectives are (1) a) to test  the hypothesis that long-term  suppressive antiviral treatment for [ADDRESS_293899] occurrence of new or worsening anterior segment 
ocular disease ( dendriform epi[INVESTIGATOR_242068], stromal keratitis, endothelial ker atitis, and/or iritis ) compared to 
placebo by 18 months ; and b ) to test the hypothesis that the occurrence of new or worsening disease in the [ADDRESS_293900] treatment period is reduced for participants treated with valacyclovir compared to placebo;  and (2)  to 
test the hypothesis that suppressive treatment for 12 months with oral valacyclovir 1000 mg daily reduces the 
Zoster Eye Disease Study (ZEDS)  Version 3.[ADDRESS_293901] herpetic neuralgia (PHN) compared to placebo at 12 and 18 months in 
patients with HZO.  
 
To evaluate these hypotheses, the following endpoint s will be evaluated:  
 
Primary Efficacy  Endpoint:  
The primary endpoint is the time to first occurrence of new or worsening epi[INVESTIGATOR_242070], stromal keratitis, endothelial keratitis, and/or iritis due to HZO, accompanied by  [CONTACT_094]-specified changes  
in treatment for the same disease manifestation  of HZO (see MOP) during the twelve months of treatment. The 
primary endpoint is compared for participants randomized to study medication or placebo.  
 
To assess the primary objectives, study participants  will be monitored at each visit for new or worsening any of 
the following conditions  (see MOP for definitions) : 
  
1. Dendriform epi[INVESTIGATOR_242068]:  
2. Stromal keratitis  
a. Without ulceration  
b. With ulceration  
3. Endothelial keratitis  
4. Iritis  
 
The endpoint of first occurrence of new or worsening dendriform epi[INVESTIGATOR_242068], stromal keratitis, 
endothelial keratitis, and/or iritis will be determined by [CONTACT_242190] (see MOP),  as there are no validated confirmatory biomarkers or other tests.    
 
Secondary Efficacy  Endpoints:  
To assess the secondary objectives, the study participants  will be monitored at each visit for the following:  
1. Time to development and number of epi[INVESTIGATOR_242096], 
stromal keratitis, endothelial keratitis, and/or iritis due to HZO , requiring pre -specified changes in 
treatment (see MOP) , during the 18 months following  randomization, that includes  the 6 months 
following cessation of treatment ; and during the [ADDRESS_293902] zoster with RZV on outcomes.   
4. Development of specific manifestations of HZO, classified as dendriform epi[INVESTIGATOR_242068], stromal 
keratitis (all types), endothelial keratitis, iritis  requiring pre -specified changes in treatment (see 
MOP) , neurotrophic keratopathy with or without melting and/or microbial superinfection, epi[INVESTIGATOR_227], 
and/or scleritis  during the twelve months of treatment .  
5. Secondary glaucoma as determined by [CONTACT_242160].  
 
Exploratory Efficacy Endpoints :  
1. Changes in strength and/or frequency of prescribed topi[INVESTIGATOR_242095] 12 and 18 months .  
2. Occurrence of stroke  
3. Occurrence of temporal arteritis/giant cell arteritis  
4. Occurrence of  myocardial infarction  
Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  44 5. Occurrence of new or worsening malignancy  
a. Solid tumor (other than non -melanoma skin cancer)  
b. Hematologic malignancy  
c. Lymphoma.  
6. Time to development and number of epi[INVESTIGATOR_242096], 
stromal keratitis, endothelial keratitis, and/or iritis  due to HZO , with a  recent substantial reduction in 
treatment (see MOP) during [ADDRESS_293903] documentation of an epi[INVESTIGATOR_242062], stromal keratitis, endothelial 
keratitis, and/or iritis due to Her pes Zoster that was diagnosed in the past year.  Eligible study participants will 
be randomized via a computer IXRS system following confirmation of eligibility within PCC in 4 strata defined 
by [CONTACT_242191] (less than 60 years, or 60 years and greater , at time of HZO onset) and by [CONTACT_242192] (recent onset:  HZO diagnosed within 6 months of the enrollment/ randomization visit; chronic:  
HZO diagnosed 6 or more months prior to the enrollment/randomization visit).  
 
10.4.2  ANALYSIS OF T HE PRIMARY EFFICACY END POINT(S)  
 
The primary endpoint is the time from randomization to development of the first occurrence of any new or 
worsening dendriform epi[INVESTIGATOR_242068], stromal keratitis, endothelial keratitis, and/or iritis due to HZO, 
diagnosed by a change in clinical slit lamp biomicroscopy examination and accompanied by [CONTACT_242193] (see MOP) by 12 months of treatment with valacyclovir compared to placebo.   
 
The objective of the analysis of the primary endpoint is to compare cumulative failure rates (failure defined as 
an epi[INVESTIGATOR_242117], stromal keratitis, endothelial keratitis, and/or 
Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  45 iritis) in the valacyclovir tr eated groups with the placebo treated group by 12 months (treatment completion). 
Kaplan -Meier curves will be plotted by [CONTACT_1570] (overall and within strata) and 95% confidence intervals 
(adjusted for interim analyses ) for the difference between the 12-month cumulative failure rates will be 
estimated (overall and within strata). Results will also be plotted within strata and by [CONTACT_242194].  
 
The primary study an alysis will be based on a stratified log -rank (2-sided)  test with adjustment for stratification 
factors (age, and recent onset vs. chronic disease).  
 
Details of all analyses , including sensitivity analyses  are provided in the SAP. For example, analyses will be 
provided that incorporate adjustments of study medication to one [ADDRESS_293904] 2 pi[INVESTIGATOR_36832] ; and that evaluate the impact of study drug discontinuation by 
[CONTACT_1570].  
 
10.4.3 ANALYSIS  OF THE SECONDARY EN DPOINT(S)  
 
Secondary endpoints are listed in Section 10.[ADDRESS_293905] one dose of the assigned 
study drug will comprise the as -treated population , the primary analysis dataset for safety.  
The analysis datasets f or safety are described in Section  10.3 ( Analysis Datasets) above .  Details are provided 
in SAP .  
The occurrence of acute kidney failure , defined as requiring temporary or permanent dialysis,  in these patients 
will be monitored using a safety monitoring rule as  described in the SAP  and compared between the two 
treatment groups .  
  
SAEs will be analyzed in a similar manner.  For all safety events, the rates of study drug termination will be 
summarized and compared by [CONTACT_242195].  
   
10.4.6 ADHERENCE  AND RETENTION ANALY SES   
 
Study recruitment , retention , and adherence will be monitored by [CONTACT_242196]. For each 
PCC, numbers of patients screened,  numbers randomized,  numbers of ineligible patients, treatment 
compliance as measured by [CONTACT_21173][INVESTIGATOR_242118] , protocol deviations, timeliness of data 
reporting and q uery resolution, numbers of  queries/ study participant , and additional monitoring measu res will 
Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  46 be provided by [CONTACT_242197].  All results will be summarized over time using descriptive 
statistics, graphical displays, and frequency distributions as appropriate.  Retention rates by [CONTACT_242198] .  
 
10.4.7  BASELINE DESCRIPTI VE STATISTICS  
 
Plans for the comparison of baseline characteristics between the two randomized treatment groups are 
provided in the SAP.  
  
10.4.8 PLANNED INTERIM ANA LYSES  
 
The interim analysis plan is described in the SAP.   
 
[IP_ADDRESS] SAFETY REVIEW  
 
For ethical reasons , an independent DSMC appointed by [CONTACT_242183] (NEI), will monitor study 
participant safety and review performance of the trial at regular intervals during the trial. The primary objective 
of these interim safety analyses is to ensure the safety of the study participants randomized in the trial.  This 
interim monitoring will involve a review of  study  participant recruitment, compliance with the study protocol, 
status of data collection, and other fac tors that reflect the overall progress and integrity of the study.  Formal 
interim analysis of efficacy will evaluate the accumulating endpoint data by [CONTACT_1570].  The interim 
monitoring plan is described in the SAP.   
 
[IP_ADDRESS] EFFICACY REVIEW  
. 
Interim  analysis(es) for efficacy  by [CONTACT_242199].     
 
Judgment concerning the continuation of the study will involve not only the magnitude of observed differences 
between randomized strategi es and degree of statistical significance, but also careful consideration of many 
other important factors including the need for precise parameter estimation, the overall progress and integrity 
of the trial including the frequency of  serious  adverse events associated with active study medication, and 
information available from other studies at the time of DSMC deliberations . 
 
10.4.9  ADDITIONAL SU B-GROUP ANALYSES  
 
Analyses of primary and secondary endpoints will be presented by [CONTACT_1534], by [CONTACT_242200], cancer  among others , and by [CONTACT_242201] a s by [CONTACT_547].  Details are 
provided in the SAP.  Pre-specified subgroup analyses will be provided in the SAP.  
 
10.4.10 MULTIPLE COMPARISON/MULTIPLIC ITY 
 
A statistical adjustment for interim efficacy analyses is incorporated into for the analysis of the primary 
endpoint. No further  adjustments for multiplicity are incorporated; any adjustments for multiplicity developed for 
the seco ndary analyses for the final study protocol will be incorporated into the SAP prior to unmasking and 
analysis of results.  
Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  47  
10.4.11 EXPLORATORY ANALYSES  
 
Exploratory analyses to compare the rates of occurrence of each of the exploratory endpoints described above 
will be conducted  as described in the SAP.   
 
10.5 SAMPLE SIZE  
 
The overall study sample size is based on the primary endpoint of epi[INVESTIGATOR_242119], stromal keratitis, endothelial keratiti s, and/or iritis accompanied by [CONTACT_094] -specified changes in 
treatment (see MOP)  by [ADDRESS_293906] as described above.  On the basis of available data, the 
12-month cumulative failure rate for the primary endpoint in the placebo group was estimated at 30% among 
study participants.  
 
Under the assumption that the cumulative 12 month failure rate in the placebo group is 30% w ith approximately 
390 study participants randomized to each of the two treatment groups, ( including a planned  interim analysis) 
we can detect a difference between the placebo and valacyclovir treated groups in failure rate at 12 months 
(treatment completion) of +/ -8.7% (to 21.3% in the valacyclovir group), an approximately 30% treatment effect, 
with a two -sided al pha = 0.05 and 80% power  (without adjustment for interim analyses)   These considerations 
are equivalent to a detectable hazard ratio for failure on valacyclovir relative to placebo of 0.[ADDRESS_293907] for the comparison of the distributions of failure times between the two groups. [Calculations from 
EAST 6.5, Cytel, 2018] We estimate that approximately 780 study participants can be randomized into this 
study over an estimated 7-year accrual period.  All randomized study participants  will be incl uded in the intent -
to-treat analysis to compare cumulative failure rates by 12 months  (failure time is defined as from 
randomization to the development of first epi[INVESTIGATOR_242117], stromal 
keratitis, endothelial ker atitis, and/or iritis) in the valacyclovir arm and placebo arm.  [ZEDS SAP provides a 
complete description of the approach].  
 
Sample size  may be re-estimated using aggregate event rates  as described in the SAP.   
 
10.6 MEASURES TO MINIM IZE BIAS  
 
10.6.1 ENROLLMENT/ RANDOMIZ ATION/ MASKING PROCE DURES  
 
Eligible study participants will be randomized centrally using the IXRS web -based interactive computerized 
system (see MOP). Study participants will be randomized following confirmation of eligibility by [CONTACT_242202], defined by [CONTACT_242203] (less than 60 years or 60 years and greater) 
and by [CONTACT_242127] (recent onset defined as HZO diagnosed within 6 months of enrollment/  
randomization, or chronic defined as HZO diagnosed 6 months or more prior to enrollment/randomization). The 
IXRS system allows PCC staff to log in and obtain the masked randomization assignment and supply 
assignment for individual study participants after on -line confirmation of eligibilit y and informed consent is 
obtained.  The IXRS will provide electronic file s with randomization numbers to the DCC for supply labeling 
prior to sending supplies to centers. Confirmation of eligibility and randomization and supply assignments are 
then incorp orated into the) Electronic Data Capture clinical trials database and become part of the study files.  
Zoster Eye Disease Study (ZEDS)  Version 3.[ADDRESS_293908] UDY BLIND/ PARTICIPANT  CODE  
 
A 24-7 helpline will be available for unmasking by [CONTACT_242204] a medical emergency 
that requires unmasking for the safety of the study participant.  (See MOP)  
 
11 SOURCE DOCUMENTS AN D ACCESS TO SOURCE D ATA/DOCUMENTS  
 
Each PCC will maintain appropriate medical and research records for this trial, in compliance with ICH E6 , and 
regulatory and institutional requirements for the protection of confidentiality of participants.  
 
Source documents contain source data and include medical records,  paper CRFs and  images and all other 
information necessary to reconstruct and evaluate the clinical trial  (see MOP) .  
 
The study investigators will permit study -related monitoring, audits, and inspections by [CONTACT_1201], the NEI, 
government regulatory agencies , and NYULMC st aff of all study -related documents and the capability for 
inspections of study -related facilities.  
 
12 QUALITY ASSURANCE AN D QUALITY CONTROL  
 
Quality control procedures will be implemented beginning with the data entry system and data QC checks that 
will be run on the database will be generated. Any missing data or data anomalies will be communicated to the 
site(s) for clarification/resolution . 
 
Following written SOPs, the monitors will verify that the clinical trial is conducted and data are generated, 
documented (recorded), and reported in compliance with the protocol, GCP, and the applicable regulatory 
requirements (e.g., regulations of the National Eye Institute of the National Institutes of Health (NEI/NIH ), the 
Food And Drug Administration (FDA) and t he International Council for Harmonisation  (ICH)). 
 
The PCCs  will provide direct access to all study related sites, source data/documents, and reports for the 
purpose of monitoring and auditing by  [CONTACT_122456],  NEI, and inspection by [CONTACT_242205]. 
 
See MOP for details on QA and QC processes.  
 
13 ETHICS/PROTECTION OF  HUMAN SUBJECTS  
 
13.[ADDRESS_293909]  
 
Zoster Eye Disease Study (ZEDS)  Version 3.[ADDRESS_293910] (CIRB) or, as required, to IRBs at PCCs for formal approval of 
the study conduct. The decision of the IRB concerning the conduct of the study will be made in writing to the 
study investigators and a copy of this decision will be provided to the CC before commence ment of the study. 
Annual renewals will be submitted to the CC.  
 
13.[ADDRESS_293911]  
 
The protocol, informed consent form(s), recruitment materials, and all participant materials will be submitted to 
the IRB for review and approval.  Approval of both the protocol and the consent form must be obtained before 
any study participant is enrolled.  Any amendment to the protocol will require review and approval by [CONTACT_242206].  All changes to the consent for m will be IRB approved; a 
determination will be made regarding whether previously consented participants need to be re -consented.  
 
Withdrawal of IRB Approval  
A study investigator shall report to the CC a withdrawal of approval by [CONTACT_093]’s reviewing IRB as soon 
as a possible, but no later than [ADDRESS_293912].  
 
13.3.2 CONSENT PROCEDURES AND DOCUMENTATION  
 
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the study and 
continues throughout the individual’s study participatio n.  Written informed consent will be obtained from all 
potential study participants on an approved consent form.   Potential study participants will be provided 
sufficient information to make an informed decision about their participation in the study.  The investigator will 
explain the research study to the potential study participant and answer any questions that may arise.  All 
potential study participants will receive a verbal explanation in terms suited to their comprehension of the 
purposes, procedure s, and potential risks of the study and of their rights as research participants.  Potential 
study p articipants will have the opportunity to carefully review the written consent form and ask questions prior 
to signing.   The potential study participants should have the opportunity to discuss the study with their 
surrogates or think about it prior to agreeing to participate. The formal consent of a study participant, using the 
IRB approved consent form, must be obtained before that study participant undergoes any study procedure.  
The consent form must be signed and dated by [CONTACT_242207] -designated 
research professional obtaining the consent.  A copy of the informed consent document will be given to the 
participants for their records.  The rights and welfare of the participants will be protected by [CONTACT_242208].  
Zoster Eye Disease Study (ZEDS)  Version 3.[ADDRESS_293913] the risk of loss of confidentiality, the study will follow the procedures specified by [CONTACT_242209], central IRB or IRBs of the PCCs.  Study participants will be assigned a unique identification 
number using no identifying information. Personal identifying information such as name, address, driver’s 
license, or Social Security Number will not be entered into the database.  The CC at NYULMC is IRB approved 
and ha s experience in managing PHI  and are extremely prudent in keepi[INVESTIGATOR_242120] a number of standard operating procedures.  Transmission of informed consent forms and 
records with any PHI for central source document  verification by [CONTACT_242210], or 
secure fax, or mail.   The control of access to databases will be managed centrally by [CONTACT_242211].  This protects data from unauthorized  view and 
modifications and from inadvertent loss or damage.   The CC has an extensive data security infrastructure. 
Materials that contain PHI will be stored securely at PCCs .  This information will be retained by [CONTACT_242212].  If a PCC closes and cannot continue to 
follow enrolled participants, they may be transferred, with the study participant’s consent, t o another PCC.  
 
Information about study participants will be managed according to the requirements of the Health Insurance 
Portability and Accountability Act (HIPAA), including obtaining written authorization to collect and use protected 
health information  (PHI).  In the event that a study participant revokes authorization to collect or use PHI, the 
study investigator retains the ability to use all information collected prior to this revocation.   In this situation, the 
study investigator should attempt to o btain permission to collect at least information that the study participant is 
alive at the end of their scheduled study period.  
 
13.4.[ADDRESS_293914] be in a double -locked secure location and/or password 
Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  51 protected, encrypted electroni c files at each PCC in compliance with local IRB PHI will be redacted before 
submission for central monitoring  (see MOP and SAP) . 
 
CC staff will provide the PCC staff with a visit checklist to ensure that all required data are collected at each 
visit and i n the preferred order of data collection.  A secure, compliant, web based electronic data capture 
(EDC) system will be developed to process, edit and store all study data in a centralized database. PCC staff 
will document relevant information on source documents and enter data into the EDC system.  A 
comprehensive data management methodology will be implemented.  All data will be reviewed for 
completeness, accuracy and logical consistency though out the duration of the study.  Final data cleanup will 
be completed shortly after the last  study  partici pant visit, at which time  the study database will be locked and 
provided to the study statistician for analyses.  
 
14.2  STUDY RECORDS R ETENTION  
 
It is the study investigator’s responsibility to retain all study documents in accordance with federal regulati ons 
and any applicable local state and institutional requirements after the investigator has been informed by [CONTACT_242213].   
 
14.3 PROTOCOL DEVIATIONS  
 
Protocol Deviations:  
A protocol deviation is any noncompliance with the clinical study protocol, Good Clinical Practice, or MOP 
requirements. The noncompliance may be on the part of the study participant, the investigator, or PCC study 
staff. As a result of deviations, corrective actions  are to be developed by [CONTACT_242214].  
 
These practices are consistent with ICH E6:  
 Compliance with Protocol, Sections 4.5.1, 4.5.2, 4.5.3, and 4.5.4.  
 Quality Assurance and Quality Control, Section 5.1.1  
 Noncompliance, Sections 5.20.[ADDRESS_293915] be addressed in study participant’s source documents and promptly 
reported within the EDC system. Protocol deviations must be reported to the PCC’s responsible IRB per their 
guidelines and the DSMC at each review. Furt her details about the handling of protocol deviations are included 
in the MOP.  
 
14.4 PUBLICATION AND DAT A SHARING POLICY  
 
The Publication s Committee will authorize access to study data.  
 
All data access will follow guidelines described in the NIH Data Sha ring Policy 
(http://grants.nih.gov/grants/gwas/index.htm), the Food and Drug Administration Amendments Act of 2007 
(FDAAA), and ClinicalTrials.gov.  
 
Zoster Eye Disease Study (ZEDS)  Version 3.[ADDRESS_293916] the primary responsibility for the 
publica tion of the results of the study.  The DSMC will review the report of the primary results of the study prior 
to submission for publication.   
 
Any PCC investigator involved with this study is obligated to provide the sponsor (NYULMC) with complete test 
results and all data derived from the study.  Primary and secondary reports of study findings will be published 
in peer -reviewed journals.  Proposals for presentations and publications incorporating study data must be 
submitted for review by [CONTACT_242215].  
 
No PCC  investigator  is permitted to present or publish data obtained during the conduct of this trial without 
prior approval from the publications committee.  PCC investigators must submit a proposal requesting access 
to trial data.   
 
The full publications policy may be found in the MOP.  
 
[ADDRESS_293917] that is appropriate to their participation in the trial. The study 
leadership in conjunction with the NEI has established policies and procedures for all study grou p members to 
disclose all conflicts.  Details are in the MOP.  
 
17  LITERATURE REFER ENCES  
1. Miserocchi E [et al.] Clinical features of ocular herpetic infection in an italian referral center. 
[Journal]  // Cornea.  - Jun 2014.  - pp. 33(6):565 -70. doi: 10.1097 /ICO.0000000000000129. PMID: 
24763121 [PubMed – indexed fro MEDLINE].  
Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  53 2. Pavan -Langston D, Yamamoto S and Dunkel E C Delayed herpes zoster pseudodendrites. 
Polymerase chain reaction detection of viral DNA and a role for antiviral therapy. [Journal]  // Arch 
Ophthalmol.  - Nov 1995.  - pp. 113(11):1381 -5. PMID: 7487598 [PubMed - indexed for MEDLINE].  
3. Hu A Y [et al.] Late varicella -zoster virus dendriform keratitis in patients with histories of herpes 
zoster ophthalmicus. [Journal]  // Am J Ophthalmol.  - Feb 2010.  - pp. 149(2):214 -220.e3. doi: 
10.1016/j.ajo.2009.08.030. Epub 2009 Nov 11. PMID: 19909942 [PubMed - indexed for MEDLINE].  
4. No authors listed Acyclovir for the prevention of recurrent herpes simplex virus eye disease. 
Herpetic Eye Disease Study Group. [Journa l] // N Engl J Med.  - Jul 30, 1998.  - pp. 339(5):300 -6. 
PMID: 9696640 [PubMed - indexed for MEDLINE].  
5. Aggarwal S, Cavalcanti B M and Pavan -Langston D Treatment of pseudodendrites in herpes zoster 
ophthalmicus with topi[INVESTIGATOR_242121] 0.15% gel. [Journal]  // Cornea.  - Feb 2014.  - pp. 33(2):109 -13. 
doi: 10.1097/ICO.0000000000000020. PMID: 24322809 [PubMed - in process].  
6. Gilden, D., White, T., Khmeleva, N., Heintzman, A., Choe, A., Boyer, P. J., et al. (2015, May). 
Prevalence and distribution of VZV in tempora l arteries of patients with giant cell arteritis. 
Neurology., 84(19):1948 -55. doi: 10.1212/WNL.0000000000001409. Epub 2015 Feb 18. PMID: 
25695965 [PubMed - indexed for MEDLINE] PMCID: PMC4433460 [Available on 2016 -05-12]. 
7. Gilden D [et al.] Clinical and mol ecular aspects of varicella zoster virus infection. [Journal]  // Future 
Neurol.  - Jan 1, 2009.  - pp. 4(1):103 -117. PMID: 19946620 [PubMed] PMCID: PMC2782836.  
8. Mahalingam R [et al.] Persistence of varicella -zoster virus DNA in elderly patients with postherpe tic 
neuralgia. [Journal]  // J Neurovirol.  - Mar 1995.  - pp. 1(1):130 -3. PMID: 9222350 [PubMed - indexed 
for MEDLINE].  
9. Nagel M A [et al.] The value of detecting anti -VZV IgG antibody in CSF to diagnose VZV 
vasculopathy. [Journal]  // Neurology.  - Mar 27, 200 7. - pp. 68(13):1069 -73. Epub 2007 Feb 7. 
PMID: 17287447 [PubMed - indexed for MEDLINE].  
10. Baratz K H The role of antiviral therapy after the resolution of acute herpes simplex keratitis or 
acute herpes zoster ophthalmicus. [Journal]  // Arch Ophthalmol.  - Jan 2012.  - pp. 130(1):108 -10. 
doi: 10.1001/archophthalmol.2011.379. PMID: 22232479 [PubMed - indexed for MEDLINE].  
11. Nagel M A and Gilden D Neurological complications of varicella zoster virus reactivation. [Journal]  // 
Curr Opin Neurol.  - Jun 2014.  - pp. 27( 3):356 -60. doi: 10.1097/WCO.0000000000000092. PMID: 
24792344 [PubMed - in process].  
12. Nagel M A [et al.] Varicella zoster virus in the temporal artery of a patient with giant cell arteritis. 
[Journal]  // J Neurol Sci.  - Dec 15, 2013.  - pp. 335(1 -2):228 -30. d oi: 10.1016/j.jns.2013.09.034. 
Epub [ADDRESS_293918] 2. PMID: 24125020 [PubMed - indexed for MEDLINE] PMCID: PMC3848200 
[Available on 2014/12/15].  
13. Nagel M A [et al.] Multifocal VZV vasculopathy with temporal artery infection mimics giant cell 
arteritis. [Journal]  // Neurology.  - May 28, 2013.  - pp. 80(22):2017 -21. doi: 
Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  54 10.1212/WNL.0b013e318294b477. Epub 2013 May 1. PMID: 23635966 [PubMed - indexed fo r 
MEDLINE] PMCID: PMC3716402.  
14. Takase H [et al.] Comparison of the ocular characteristics of anterior uveitis caused by [CONTACT_242216], varicella -zoster virus, and cytomegalovirus [Journal]  // Jpn J Ophthalmol..  - Aug 16, 
2014.  - pp. [Epub ahead of pr int] PMID: 25124341 [PubMed - as supplied by [CONTACT_242217]].  
15. Nagel M A [et al.] Persistence of varicella zoster virus DNA in saliva after herpes zoster. [Journal]  // 
J Infect Dis.  - Sep 15, 2011.  - pp. 204(6):820 -4. doi: 10.1093/infdis/jir425. PMID: 21849278 
[PubMed - indexed for MEDLINE] PMCID: PMC3156921.  
16. Breuer J [et al.] Herpes zoster as a risk factor for stroke and TIA: a retrospective cohort study in the 
[LOCATION_006]. [Journal]  // Neurology.  - Jan 21, 2014.  - pp. 82(3):206 -12. doi: 
10.1212/WNL.0000000000000038. Epu b 2014 Jan 2. PMID: 24384645 [PubMed - indexed for 
MEDLINE] PMCID: PMC3902756.  
17. Wang C C [et al.] Herpes zoster infection associated with acute coronary syndrome: a population -
based retrospective cohort study. [Journal]  // Br J Dermatol.  - May 2014.  - pp. 1 70(5):1122 -9. doi: 
10.1111/bjd.[ZIP_CODE]. PMID: 24354564 [PubMed - in process].  
18. Wu P Y [et al.] Increased risk of cardiovascular events in patients with herpes zoster: a population -
based study. [Journal]  // J Med Virol.  - May 2014.  - pp. 86(5):772 -7. doi: 10.1 002/jmv.[ZIP_CODE]. Epub 
2014 Jan 30. PMID: 24482346 [PubMed - in process].  
19. Nagel M and Gilden D Editorial commentary: varicella zoster virus infection: generally benign in 
kids, bad in grown -ups. [Journal]  // Clin Infect Dis.  - Jun 2014.  - pp. 58(11):1504 -6. doi: 
10.1093/cid/ciu099. Epub 2014 Apr 2. PMID: 24700655 [PubMed - in process] PMCID: 
PMC4017890 [Available on 2015/6/1].  
20. Barron B A [et al.] Herpetic Eye Disease Study. A controlled trial of oral acyclovir for herpes simplex 
stromal keratitis. [Journal]  // Ophthalmology.  - Dec 1994.  - pp. 101(12):1871 -82. PMID: 7997323 
[PubMed - indexed for MEDLINE].  
21. Young R C [et al.] Incidence, recurrence, and outcomes of herpes simplex virus eye disease in 
Olmsted County, Minnesota, 1976 -2007: the effect of oral antivira l prophylaxis. [Journal]  // Arch 
Ophthalmol.  - Sep 2010.  - pp. 128(9):1178 -83. doi: 10.1001/archophthalmol.2010.187. PMID: 
20837803 [PubMed - indexed for MEDLINE] PMCID: PMC3103769.  
22. Hawthorne K M, Dana R and Chodosh J Delayed type hypersensitivity in the p athogenesis of 
recurrent herpes stromal keratitis. [Journal]  // Semin Ophthalmol.  - Jul-Sep 2011.  - pp. 26(4 -5):246 -
50. doi: 10.3109/08820538.2011.588659. Review. PMID: 21958170 [PubMed - indexed for 
MEDLINE].  
23. Ghaznawi N [et al.] Herpes zoster ophthalmicus : comparison of disease in patients 60 years and 
older versus younger than 60 years. [Journal]  // Ophthalmology.  - Nov 2011.  - pp. 118(11):2242 -50. 
doi: 10.1016/j.ophtha.2011.04.002. Epub 2011 Jul 23. PMID: 21788078 [PubMed - indexed for 
MEDLINE].  
Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  55 24. Sy A [et  al.] Practice patterns and opi[INVESTIGATOR_242122]. [Journal]  // Cornea.  - Jul 2012.  - pp. 31(7):786 -90. doi: 
10.1097/ICO.0b013e31823cbe6a. PMID: 269677 [PubMed - indexed for MEDLINE] PMCID: 
PMC3729033 . 
25. Sackel D J, Castano E and Cohen E J Physician Survey for Study of Suppressive Antiviral 
Treatment to Reduce Chronic Ocular Disease and Postherpetic Neuralgia After Herpes Zoster 
Ophthalmicus. [Journal]  // Eye Contact [CONTACT_19550].  - Jun 2, 2014.  - pp. [Epub ahea d of print] PMID: 
24892787 [PubMed - as supplied by [CONTACT_242217]].  
26. Insinga R P [et al.] The incidence of herpes zoster in a [LOCATION_002] administrative database. 
[Journal]  // J Gen Intern Med.  - Aug 2005.  - pp. 20(8):748 -53. PMID: 16050886 [PubMed - indexed 
for MEDLINE] PMCID: PMC1490195.  
27. Rimland D and Moanna A Increasing incidence of herpes zoster among Veterans. [Journal]  // Clin 
Infect Dis.  - Apr 1, 2010.  - pp. 50(7):1000 -5. doi: 10.1086/651078. PMID: 20178416 [PubMed - 
indexed for MEDLINE].  
28. Kawai K, Gebre meskel B G and Acosta C J Systematic review of incidence and complications of 
herpes zoster: towards a global perspective. [Journal]  // BMJ Open.  - Jun 10, 2014.  - pp. 
4(6):e004833. doi: 10.1136/bmjopen -2014 -004833. PMID: 24916088 [PubMed] PMCID: 
PMC406781 2. 
29. Liesegang T J Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and 
morbidity. [Journal]  // Ophthalmology.  - Feb 2008.  - pp. 115([ADDRESS_293919]):S3 -12. doi: 
10.1016/j.ophtha.2007.10.009. Review. PMID: 18243930 [PubMed - indexed f or MEDLINE].  
30. Johnson R W [et al.] The impact of herpes zoster and post -herpetic neuralgia on quality -of-life. 
[Journal]  // BMC Med.  - Jun 21, 2010.  - pp. 8:37. doi: 10.1186/1741 -7015 -8-37. PMID: 20565946 
[PubMed - indexed for MEDLINE] PMCID: PMC2905321.  
31. Borkar D S [et al.] Incidence of herpes zoster ophthalmicus: results from the Pacific Ocular 
Inflammation Study. [Journal]  // Ophthalmology.  - Mar 2013.  - pp. 120(3):451 -6. doi: 
10.1016/j.ophtha.2012.09.007. Epub 2012 Dec 1. PMID: 23207173 [PubMed - indexe d for 
MEDLINE] PMCID: PMC3594416.  
32. Ultsch B [et al.] Herpes zoster in [LOCATION_013]: quantifying the burden of disease. [Journal]  // BMC 
Infect Dis.  - Jun 16, 2011.  - pp. 11:173. doi: 10.1186/1471 -2334 -11-173. PMID: 21679419 [PubMed 
- indexed for MEDLINE] PMCID: PMC3141411.  
33. Studahl M, Petzold M and Cassel T Disease burden of herpes zoster in Sweden --predominance in 
the elderly and in women - a register based study. [Journal]  // BMC Infect Dis.  - Dec 12, 2013.  - pp. 
13:586. doi: 10.1186/1471 -2334 -13-586. PMID: 2433 0510 [PubMed - in process] PMCID: 
PMC3866924.  
Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  56 34. Ultsch B [et al.] Epi[INVESTIGATOR_242123]. 
[Journal]  // Eur J Health Econ.  - Dec 2013.  - pp. 14(6):1015 -26. doi: 10.1007/s10198 -012-0452 -1. 
Epub 2012 Dec 28.  PMID: 23271349 [PubMed - indexed for MEDLINE].  
35. White R R [et al.] Incremental 1 -year medical resource utilization and costs for patients with herpes 
zoster from a set of US health plans. [Journal]  // Pharmacoeconomics.  - 2009.  - pp. 27(9):781 -92. 
doi: 10. 2165/11317560 -000000000 -[ZIP_CODE]. PMID: 19757871 [PubMed - indexed for MEDLINE].  
36. De Moragas J M and Kierland R R The outcome of patients with herpes zoster. [Journal]  // AMA 
Arch Derm.  - Feb 1957.  - pp. 75(2):193 -6. PMID: 13393787 [PubMed - indexed for MEDLIN E]. 
37. Bouhassira D [et al.] Patient perspective on herpes zoster and its complications: an observational 
prospective study in patients aged over 50 years in general practice. [Journal]  // Pain.  - Feb 2012.  - 
pp. 153(2):342 -9. doi: 10.1016/j.pain.2011.10.026.  Epub 2011 Dec 3. PMID: 22138256 [PubMed - 
indexed for MEDLINE].  
38. Drolet M [et al.] The impact of herpes zoster and postherpetic neuralgia on health -related quality of 
life: a prospective study. [Journal]  // CMAJ.  - Nov 9, 2010.  - pp. 182(16):1731 -6. doi: 
10.1503/cmaj.091711. Epub [ADDRESS_293920] 4. PMID: 20921251 [PubMed - indexed for MEDLINE] 
PMCID: PMC2972323.  
39. Chen M H [et al.] Risk of depressive disorder among patients with herpes zoster: a nationwide 
population -based prospective study. [Journal]  // Psychosom M ed. - May 2014.  - pp. 76(4):285 -91. 
doi: 10.1097/PSY.0000000000000051. PMID: 24804885 [PubMed - in process].  
40. Hess T M [et al.] Treatment of acute herpetic neuralgia. A case report and review of the literature. 
[Journal]  // Minn Med.  - Apr 1990.  - pp. 73(4) :37-40. Review. PMID: 2186265 [PubMed - indexed for 
MEDLINE].  
41. Volpi A [et al.] Clinical and psychosocial correlates of post -herpetic neuralgia. [Journal]  // J Med 
Virol.  - Sep 2008.  - pp. 80(9):1646 -52. doi: 10.1002/jmv.[ZIP_CODE]. PMID: 18649332 [PubMed - 
indexed for MEDLINE].  
42. Lin H C, Chien C W and Ho J D Herpes zoster ophthalmicus and the risk of stroke: a population -
based follow -up study. [Journal]  // Neurology.  - Mar 9, 2010.  - pp. 74(10):792 -7. doi: 
10.1212/WNL.0b013e3181d31e5c. Epub 2010 Mar 3. PMID: 20200348 [PubMed - indexed for 
MEDLINE].  
43. Kang J H [et al.] Increased risk of stroke after a herpes zoster attack: a population -based follow -up 
study. [Journal]  // Stroke.  - Nov 2009.  - pp. 40(11):3443 -8. doi: 10.1161/STROKEAHA.109.562017. 
Epub [ADDRESS_293921] 8. PMID: 19815828 [PubMed - indexed for MEDLINE].  
44. Langan S M [et al.] Risk of stroke following herpes zoster: a self -controlled case -series study. 
[Journal]  // Clin Infect Dis.  - Jun 2014.  - pp. 58(11):1497 -503. doi: 10.1093/cid/ciu098. Epub 2014 
Apr 2. PMID:  24700656 [PubMed - in process] PMCID: PMC4017889.  
45. Sreenivasan N [et al.] The short - and long -term risk of stroke after herpes zoster - a nationwide 
population -based cohort study. [Journal]  // PLoS One.  - Jul 17, 2013.  - pp. 8(7):e69156. doi: 
Zoster Eye Disease Study (ZEDS)  Version 3.0 
Protocol 16-[ZIP_CODE]    March 25, 2020  
 
  57 10.1371/journ al.pone.0069156. Print 2013. PMID: 23874897 [PubMed - indexed for MEDLINE] 
PMCID: PMC3714240.  
46. Hoang -Xuan T [et al.] Oral acyclovir for herpes zoster ophthalmicus. [Journal]  // Ophthalmology.  - 
Jul 1992.  - pp. 99(7):1062 -70; discussion 1070 -1. PMID: 1495785  [PubMed - indexed for 
MEDLINE].  
47. Cobo M [et al.] Observations on the natural history of herpes zoster ophthalmicus. [Journal]  // Curr 
Eye Res.  - Jan 1987.  - pp. 6(1):195 -9. PMID: 3493883 [PubMed - indexed for MEDLINE].  
48. Gnann Jr. J W Antiviral therapy of va ricella -zoster virus infections. [Book Section]  // Human 
Herpesviruses: Biology, Therapy, and Immunoprophylaxis  / book auth. Arvin A Campadelli -Fiume 
G, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K, editors.  - Cambridge: Cambridge 
University Pre ss. Chapter 65. PMID: 21348091 [PubMed], 2007.  
49. Pavić I [et al.] Flow cytometric analysis of herpes simplex virus type 1 susceptibility to acyclovir, 
ganciclovir, and foscarnet. [Journal]  // Antimicrob Agents Chemother.  - Dec 1997.  - pp. 
41(12):2686 -92. PMI D: 9420039 [PubMed - indexed for MEDLINE] PMCID: PMC164189.  
50. Tyring S K, Baker D and Snowden W Valacyclovir for herpes simplex virus infection: long -term 
safety and sustained efficacy after 20 years' experience with acyclovir. [Journal]  // J Infect Dis.  - Oct 
15, 2002.  - pp. [ADDRESS_293922] 1:S40 -6. Review. PMID: 12353186 [PubMed - indexed for MEDLINE].  
51. Coresh J [et al.] Prevalence of chronic kidney disease in the [LOCATION_002]. [Journal]  // JAMA.  - Nov 
7, 2007.  - pp. 298(17):2038 -47. PMID: 17986697 [PubMed - indexed for MEDLINE].  
52. Lam N N [et al.] Risk of acute kidney injury from oral acyclovir: a population -based study. 
[Journal]  // Am J Kidney Dis.  - May 2013.  - pp. 61(5):723 -9. doi: 10.1053/j.ajkd.2012.12.008. Epub 
2013 Jan 10. PMID: 23312723 [PubMed - indexed f or MEDLINE].  
53. Hernandez P O [et al.] Family history and herpes zoster risk in the era of shingles vaccination. 
[Journal]  // J Clin Virol.  - Dec 2011.  - pp. 52(4):344 -8. doi: 10.1016/j.jcv.2011.08.014. Epub 2011 
Sep 15. PMID: 21924676 [PubMed - indexed for M EDLINE].  
  
Zoster Eye Disease Study (ZEDS)  Version 3.[ADDRESS_293923] 7, 2017  Clarification of the use of divided dose and reduced dose of 
the study medication.  
Correction of the Schedule of Events table.  
2.0 February 12, 2018  Clarification of secondary endpoints 1 and 3 . 
Addition of new exploratory  endpoint . 
Clarification of inclusion criterion 6 . 
Clarification of exclusion criterion 5 to include usually 
vesicular rash . 
Clarification of exclusion 6 to include use of th e new zoster 
vaccine  and temporary discontinuation of study 
medication when study participant takes the new 
vaccine . 
Clarification of the discontinuation of study medication  
when study participant develops a contraindication to 
valacyclovir . 
Clarification of the discontinuation of study medication due 
to use of open label antiviral medication . 
Correction of the use of participant diaries . 
Clarification  of the review of SAEs by [CONTACT_242218].  
 